0001179929-22-000077.txt : 20220427 0001179929-22-000077.hdr.sgml : 20220427 20220427161901 ACCESSION NUMBER: 0001179929-22-000077 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220427 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220427 DATE AS OF CHANGE: 20220427 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MOLINA HEALTHCARE, INC. CENTRAL INDEX KEY: 0001179929 STANDARD INDUSTRIAL CLASSIFICATION: HOSPITAL & MEDICAL SERVICE PLANS [6324] IRS NUMBER: 134204626 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-31719 FILM NUMBER: 22859831 BUSINESS ADDRESS: STREET 1: 200 OCEANGATE, SUITE 100 CITY: LONG BEACH STATE: CA ZIP: 90802 BUSINESS PHONE: 5624353666 MAIL ADDRESS: STREET 1: 200 OCEANGATE, SUITE 100 CITY: LONG BEACH STATE: CA ZIP: 90802 FORMER COMPANY: FORMER CONFORMED NAME: MOLINA HEALTHCARE INC DATE OF NAME CHANGE: 20020812 8-K 1 moh-20220427.htm 8-K moh-20220427
0001179929false00011799292022-04-272022-04-27

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________
FORM 8-K
______________
Current Report
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 27, 2022 (April 27, 2022)
______________
MOLINA HEALTHCARE, INC.
(Exact name of registrant as specified in its charter)
Delaware1-3171913-4204626
(State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.)
______________
200 Oceangate, Suite 100,Long Beach,California90802
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (562) 435-3666
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.001 Par Value MOHNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section13(a) of the Exchange Act.



Item 2.02.    Results of Operations and Financial Condition.
On April 27, 2022, Molina Healthcare, Inc. (the “Company”) issued a press release reporting its financial results for the first quarter ended March 31, 2022 and increasing its previously announced full-year 2022 guidance with respect to GAAP earnings per diluted share and premium revenue. The full text of the press release is included as Exhibit 99.1 to this report. The information contained in the website cited in the press release is not part of this report.
Note: The information in this Form 8-K and the exhibits attached hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01.    Financial Statements and Exhibits.
(d)     Exhibits:
Exhibit No.Description
99.1
104
Cover Page information from Molina Healthcare, Inc.’s Current Report on Form 8-K filed on April 27, 2022 formatted in iXBRL (Inline Extensible Business Reporting Language).



SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
MOLINA HEALTHCARE, INC.
Date:
April 27, 2022
By:
/s/ Jeff D. Barlow
Jeff D. Barlow
Chief Legal Officer and Secretary


EX-99.1 2 moh1q22_er.htm EX-99.1 Document
molinaa03a01a01a17.jpg
News Release
Investor Contact: Joseph Krocheski, Joseph.Krocheski@molinahealthcare.com, 562-951-8382
Media Contact: Caroline Zubieta, Caroline.Zubieta@molinahealthcare.com, 562-951-1588
Molina Healthcare Reports First Quarter 2022 Financial Results
Increases Full-Year 2022 Revenue and Earnings Guidance

Long Beach, Calif, April 27, 2022 – Molina Healthcare, Inc. (NYSE: MOH) (the “Company”) today reported first quarter 2022 GAAP earnings per diluted share of $4.39 and adjusted earnings per diluted share of $4.90. Financial results are summarized below:
Quarter ended
March 31,
 20222021
(In millions, except per-share results)
Premium Revenue$7,531$6,306
Total Revenue$7,770$6,522
GAAP:
Net Income$258$228
EPS – Diluted$4.39$3.89
Medical Care Ratio (MCR)87.1%86.8%
G&A Ratio7.4%7.3%
After-tax Margin3.3%3.5%
Adjusted:
Net Income$288$260
EPS – Diluted$4.90$4.44
G&A Ratio7.1%7.0%
After-tax Margin3.7%4.0%
See the Reconciliation of Unaudited Non-GAAP Financial Measures at the end of this release.

Quarter Highlights
As of March 31, 2022, the Company served approximately 5.1 million members, an increase of 480,000 members or 10% compared to March 31, 2021.
Premium revenue was approximately $7.5 billion for the first quarter of 2022, an increase of 19% compared to the first quarter of 2021.
GAAP earnings were $4.39 per diluted share.
Adjusted earnings were $4.90 per diluted share.
The net effect of COVID decreased net income by approximately $0.57 per diluted share in the first quarter of 2022.
The Company increased its full year 2022 premium revenue guidance to approximately $29.25 billion, compared to its previous guidance of approximately $28.5 billion.
The Company increased its full year 2022 adjusted earnings guidance to no less than $17.10 per diluted share, compared to its previous guidance of no less than $17.00 per diluted share.
-MORE-

Molina Healthcare, Inc. Announces First Quarter 2022 Results
Page 2
April 27, 2022

“We are very pleased with our first quarter results,” said Joseph Zubretsky, President and Chief Executive Officer. “We are maintaining strong momentum across each dimension of our strategy by delivering high quality health care for members, achieving meaningful top line growth, and producing attractive margins. The Company’s performance continues to validate our long-term strategy and its value creation potential.”

Premium Revenue
Premium revenue was approximately $7.5 billion for the first quarter of 2022, an increase of 19% compared to the first quarter of 2021. The higher premium revenue reflects increased organic membership in the Medicaid and Medicare lines of business and the impact of acquisitions.

Net Income
Net income for the first quarter of 2022 was $4.39 per diluted share, compared to $3.89 per diluted share in the first quarter of 2021. Adjusted net income for the first quarter of 2022 was $4.90 per diluted share, compared to $4.44 per diluted share in the first quarter of 2021. The net effect of COVID decreased the first quarter of 2022 GAAP and adjusted EPS by $0.57 per diluted share, compared to a negligible impact in the first quarter of 2021.

Medical Care Ratio
The consolidated MCR for the first quarter of 2022 was 87.1%, compared to 86.8% for first quarter of 2021. The net effect of COVID added approximately 50 basis points to the consolidated MCR. In the prior year, the net effect of COVID was negligible. In both periods, the impact varied by line of business.
The Medicaid MCR of 88.1% was in line with the Company’s long-term target. The net effect of COVID added approximately 10 basis points in the quarter.
The Medicare MCR of 86.5% was favorable to the Company’s long-term target. The net effect of COVID added approximately 190 basis points in the quarter.
The Marketplace MCR of 78.6% was in line with the Company’s long-term target and reflects the successful execution of the Company’s product repositioning strategy. The net effect of COVID added approximately 270 basis points in the quarter.

General and Administrative Expense Ratio
The G&A ratio for the first quarter of 2022 was 7.4%, compared to 7.3% for the first quarter of 2021. The adjusted G&A ratio was 7.1% for the first quarter, compared to 7.0% for the first quarter of 2021 reflecting temporary labor challenges and one-time items.

Balance Sheet
Cash and investments at the parent company were $250 million as of March 31, 2022, compared to $348 million as of December 31, 2021.

Cash Flow
Operating cash flow for the first quarter of 2022 was $363 million and was lower compared to the first quarter of 2021, primarily due to the net impact of timing differences in government receivables and payables and partially offset by an increase in net earnings.

-MORE-

Molina Healthcare, Inc. Announces First Quarter 2022 Results
Page 3
April 27, 2022
2022 Guidance
Premium revenue for full year 2022 is now expected to be approximately $29.25 billion, compared to the previous guidance of approximately $28.5 billion. The guidance increase of approximately $750 million includes the extension of the Public Health Emergency from April to July, higher Marketplace membership, and pass through revenue payments.
The Company increased its full year 2022 adjusted earnings guidance to no less than $17.10 per diluted share, compared to the previous guidance of no less than $17.00 per diluted share, reflecting:
Strong first quarter 2022 performance and expected underlying business strength in the rest of the year; and,
Margin associated with the increase in premium revenue guidance; partially offset by,
A $0.50 per diluted share increase in projected net effect of COVID.
See the Reconciliation of Unaudited Non-GAAP Financial Measures at the end of this release.

Conference Call
Management is hosting a conference call and webcast to discuss Molina Healthcare’s first quarter 2022 results at 8:00 a.m. Eastern Time on Thursday, April 28, 2022. The number to call for the interactive teleconference is (877) 883-0383 and the confirmation number is 6168107. A telephonic replay of the conference call will be available through Thursday, May 12, 2022, by dialing (877) 344-7529 and entering confirmation number 3378643. A live audio broadcast of this conference call will be available on Molina Healthcare’s website, molinahealthcare.com. A 30-day online replay will be available approximately an hour following the conclusion of the live broadcast.

About Molina Healthcare
Molina Healthcare, Inc., a FORTUNE 500 company (currently ranked 155), provides managed healthcare services under the Medicaid and Medicare programs and through the state insurance marketplaces. Molina Healthcare served approximately 5.1 million members as of March 31, 2022, located across 19 states. For more information about Molina Healthcare, please visit molinahealthcare.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This earnings release and the Company’s accompanying oral remarks contain forward-looking statements regarding its 2022 guidance, as well as its plans and expectations regarding future developments. Actual results could differ materially due to numerous known and unknown risks and uncertainties. These risks and uncertainties are discussed under the headings “Forward-Looking Statements,” and “Risk Factors,” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, which is on file with the SEC, and also in its Quarterly Report on Form 10-Q for the three months ended March 31, 2022, which the Company expects to file on or about April 28, 2022.
These reports can be accessed under the investor relations tab of the Company’s website or on the SEC’s website at sec.gov. Given these risks and uncertainties, the Company can give no assurances that its forward-looking statements will prove to be accurate, or that any other results or developments projected or contemplated by its forward-looking statements will in fact occur, and the Company cautions investors not to place undue reliance on these statements. All forward-looking statements in this release represent the Company’s judgment as of April 27, 2022, and, except as otherwise required by law, the Company disclaims any obligation to update any forward-looking statement to conform the statement to actual results or changes in its expectations.
-MORE-

Molina Healthcare, Inc. Announces First Quarter 2022 Results
Page 4
April 27, 2022
MOLINA HEALTHCARE, INC.
UNAUDITED CONSOLIDATED STATEMENTS OF INCOME
Three Months Ended
 March 31,
 20222021
 (In millions, except per-share amounts)
Revenue:
Premium revenue$7,531 $6,306 
Premium tax revenue 208 187 
Investment income 11 
Other revenue20 20 
Total revenue7,770 6,522 
Operating expenses:
Medical care costs6,563 5,474 
General and administrative expenses571 473 
Premium tax expenses208 187 
Depreciation and amortization40 33 
Other16 20 
Total operating expenses7,398 6,187 
Operating income372 335 
Other expenses, net:
Interest expense28 30 
Total other expenses, net28 30 
Income before income tax expense
344 305 
Income tax expense86 77 
Net income$258 $228 
Net income per share – Diluted$4.39 $3.89 
Diluted weighted average shares outstanding
58.7 58.6 
Operating Statistics:
Medical care ratio87.1 %86.8 %
G&A ratio7.4 %7.3 %
Premium tax ratio2.7 %2.9 %
Effective income tax rate25.0 %25.2 %
After-tax margin3.3 %3.5 %

-MORE-

Molina Healthcare, Inc. Announces First Quarter 2022 Results
Page 5
April 27, 2022
MOLINA HEALTHCARE, INC.
CONSOLIDATED BALANCE SHEETS
March 31,December 31,
20222021
Unaudited
(Dollars in millions,
except per-share amounts)
ASSETS
Current assets:
Cash and cash equivalents$4,804 $4,438 
Investments2,988 3,202 
Receivables2,156 2,177 
Prepaid expenses and other current assets198 247 
Total current assets10,146 10,064 
Property, equipment, and capitalized software, net393 396 
Goodwill and intangible assets, net1,305 1,252 
Restricted investments221 212 
Deferred income taxes 114 106 
Other assets181 179 
Total assets$12,360 $12,209 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Medical claims and benefits payable$3,601 $3,363 
Amounts due government agencies 2,613 2,472 
Accounts payable, accrued liabilities and other809 842 
Deferred revenue18 370 
Total current liabilities7,041 7,047 
Long-term debt2,174 2,173 
Finance lease liabilities217 219 
Other long-term liabilities134 140 
Total liabilities9,566 9,579 
Stockholders’ equity:
Common stock, $0.001 par value, 150 million shares authorized; outstanding: 59 million shares at March 31, 2022, and 58 million shares at December 31, 2021
— — 
Preferred stock, $0.001 par value; 20 million shares authorized, no shares issued and outstanding
— — 
Additional paid-in capital218 236 
Accumulated other comprehensive loss(81)(5)
Retained earnings2,657 2,399 
Total stockholders’ equity2,794 2,630 
Total liabilities and stockholders’ equity$12,360 $12,209 
-MORE-

Molina Healthcare, Inc. Announces First Quarter 2022 Results
Page 6
April 27, 2022
MOLINA HEALTHCARE, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
Three Months Ended
March 31,
20222021
(In millions)
Operating activities:
Net income$258 $228 
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization40 33 
Deferred income taxes16 
Share-based compensation
34 24 
Other, net
(8)12 
Changes in operating assets and liabilities:
Receivables21 (98)
Prepaid expenses and other current assets(32)(15)
Medical claims and benefits payable263 168 
Amounts due government agencies 137 432 
Accounts payable, accrued liabilities and other(81)16 
Deferred revenue(352)(304)
Income taxes67 66 
Net cash provided by operating activities
363 568 
Investing activities:
Purchases of investments(403)(388)
Proceeds from sales and maturities of investments
513 308 
Purchases of property, equipment, and capitalized software
(23)(16)
Other, net (13)
Net cash provided by (used in) investing activities74 (87)
Financing activities:
Common stock withheld to settle employee tax obligations(52)(51)
Contingent consideration liabilities settled(20)(20)
Common stock purchases
— (128)
Other, net (5)(8)
Net cash used in financing activities(77)(207)
Net increase in cash, cash equivalents, and restricted cash and cash equivalents360 274 
Cash, cash equivalents, and restricted cash and cash equivalents at beginning of period
4,506 4,223 
Cash, cash equivalents, and restricted cash and cash equivalents at end of period
$4,866 $4,497 
-MORE-

Molina Healthcare, Inc. Announces First Quarter 2022 Results
Page 7
April 27, 2022
MOLINA HEALTHCARE, INC.
UNAUDITED SEGMENT DATA
(Dollars in millions)


March 31,December 31,March 31,
2022
2021
2021
Ending Membership by Segment:
Medicaid4,566,000 4,329,000 3,859,000 
Medicare148,000 142,000 126,000 
Marketplace371,000 728,000 620,000 
Total5,085,000 5,199,000 4,605,000 



Three Months Ended March 31,
20222021
Premium RevenueMedical
Margin
MCR (1)
Premium RevenueMedical
Margin
MCR (1)
Medicaid $5,980 $710 88.1 %$4,840 $604 87.5 %
Medicare 943 128 86.5 799 77 90.3 
Marketplace608 130 78.6 667 151 77.3 
Consolidated$7,531 $968 87.1 %$6,306 $832 86.8 %
(1)The MCR represents medical costs as a percentage of premium revenue.

-MORE-

Molina Healthcare, Inc. Announces First Quarter 2022 Results
Page 8
April 27, 2022
MOLINA HEALTHCARE, INC.
CHANGE IN MEDICAL CLAIMS AND BENEFITS PAYABLE
(Dollars in millions)

The Company’s claims liabilities include additional reserves to account for moderately adverse conditions based on historical experience and other factors including, but not limited to, variations in claims payment patterns, changes in utilization and cost trends, known outbreaks of disease, and large claims. The Company’s reserving methodology is consistently applied across all periods presented. The amounts displayed for “Components of medical care costs related to: Prior year” represent the amounts by which the original estimates of claims and benefits payable at the beginning of the year were more than the actual liabilities based on information (principally the payment of claims) developed since those liabilities were first reported. The following table presents the components of the change in medical claims and benefits payable for the periods indicated:
Three Months Ended
March 31,
20222021
Unaudited
Medical claims and benefits payable, beginning balance
$3,363 $2,696 
Components of medical care costs related to:
Current year6,769 5,668 
Prior year(206)(194)
Total medical care costs6,563 5,474 
Payments for medical care costs related to:
Current year4,197 3,513 
Prior year2,199 1,781 
Total paid6,396 5,294 
Acquired balances, net of post-acquisition adjustments(25)(25)
Change in non-risk and other provider payables96 (12)
Medical claims and benefits payable, ending balance
$3,601 $2,839 
Days in Claims Payable (1)
51 48 
__________________
(1)The Company calculates Days in Claims Payable using claims incurred but not paid, or IBNP, and other fee-for-service payables included in medical claims and benefits payable, and quarterly fee-for-service related costs included in medical care costs within the Company’s consolidated financial statements.

-MORE-

Molina Healthcare, Inc. Announces First Quarter 2022 Results
Page 9
April 27, 2022
MOLINA HEALTHCARE, INC.
RECONCILIATION OF UNAUDITED NON-GAAP FINANCIAL MEASURES
(In millions, except per diluted share amounts)

The Company believes that certain non-GAAP (generally accepted accounting principles) financial measures are useful supplemental measures to investors in comparing the Company’s performance to the performance of other public companies in the health care industry. The non-GAAP financial measures are also used internally to enable management to assess the Company’s performance consistently over time. These non-GAAP financial measures, presented below, should be considered as supplements to, and not as substitutes for or superior to, GAAP measures.
Adjustments represent additions and deductions to GAAP net income as indicated in the table below, which include the non-cash impact of amortization of acquired intangible assets, acquisition-related expenses, and the impact of certain expenses and other items that management believes are not indicative of longer-term business trends and operations.
Adjusted G&A Ratio represents the GAAP G&A ratio, recognizing adjustments.
Adjusted net income represents GAAP net income recognizing the adjustments, net of tax. The Company believes that adjusted net income is helpful to investors in assessing the Company’s financial performance.
Adjusted net income per diluted share represents adjusted net income divided by weighted average common shares outstanding on a fully diluted basis.
Adjusted after-tax margin represents adjusted net income, divided by total revenue.
Three Months Ended March 31,
20222021
AmountPer Diluted ShareAmountPer Diluted Share
Net income
$258 $4.39 $228 $3.89 
Adjustments:
Acquisition-related expenses (1)
19 0.33 21 0.36 
Amortization of intangible assets
18 0.30 12 0.21 
Other (2)
0.04 0.15 
Subtotal, adjustments
40 0.67 42 0.72 
Income tax effect
(10)(0.16)(10)(0.17)
Adjustments, net of tax
30 0.51 32 0.55 
Adjusted net income
$288 $4.90 $260 $4.44 
__________________
(1)Reflects non-recurring costs associated with acquisitions, including various transaction and integration costs.
(2)The three months ended March 31, 2022 includes certain non-recurring costs associated with disposal of fixed assets. The three months ended March 31, 2021 includes change in premium deficiency reserves, loss on sale of property, and restructuring costs.

-MORE-

Molina Healthcare, Inc. Announces First Quarter 2022 Results
Page 10
April 27, 2022
MOLINA HEALTHCARE, INC.
RECONCILIATION OF UNAUDITED NON-GAAP FINANCIAL MEASURES (CONTINUED)
2022 GUIDANCE


Amount
Per Diluted Share (2)
Net income
$911 $15.60 
Adjustments:
Acquisition-related expenses
47 0.80 
Amortization of intangible assets
66 1.13 
Other 0.04 
Subtotal, adjustments
116 1.97 
Income tax effect (1)
(28)(0.47)
Adjustments, net of tax
88 1.50 
Adjusted net income per diluted share
$999 $17.10 
__________________
(1)Income tax effect calculated at the statutory tax rate of approximately 23.9%.
(2)Computations assume approximately 58.4 million diluted weighted average shares outstanding.
-END-
EX-101.SCH 3 moh-20220427.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page Document link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 moh-20220427_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Address, Address Line One Entity Address, Address Line One Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Registrant Name Entity Registrant Name Written Communications Written Communications Local Phone Number Local Phone Number Entity Address, State or Province Entity Address, State or Province Soliciting Material Soliciting Material City Area Code City Area Code Document Type Document Type Document Period End Date Document Period End Date Cover [Abstract] Cover [Abstract] Entity Address, City or Town Entity Address, City or Town Pre-commencement Tender Offer Pre-commencement Tender Offer Entity File Number Entity File Number Entity Central Index Key Entity Central Index Key Amendment Flag Amendment Flag Trading Symbol Trading Symbol Entity Tax Identification Number Entity Tax Identification Number Entity Emerging Growth Company Entity Emerging Growth Company Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code EX-101.PRE 5 moh-20220427_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 6 molinaa03a01a01a17.jpg GRAPHIC begin 644 molinaa03a01a01a17.jpg M_]C_X 02D9)1@ ! @$!+ $L #_X0WK17AI9@ 34T *@ @ !P$2 , M ! $ $: 4 ! 8@$; 4 ! :@$H , ! ( $Q M ( > <@$R ( 4 D(=I 0 ! I - +<; G M$ MQL "<0061O8F4@4&AO=&]S:&]P($-3,B!-86-I;G1O 1L !0 M $ $F 2@ P $ @ @$ ! $ $N @( ! $ RU M $@ ! 2 '_V/_@ !!*1DE& $" !( $@ /_M Q!9&]B M95]#30 !_^X #D%D;V)E &2 ?_; (0 # @(" D(# D)#!$+"@L1%0\, M# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P, M# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P, M# P,# P,# P,# P,# P,# P,# P,_\ $0@ 0P"@ P$B (1 0,1 ?_= 0 M"O_$ 3\ $% 0$! 0$! , 0($!08'" D*"P$ 04! 0$! 0$ M 0 " P0%!@<("0H+$ !! $# @0"!0<&" 4###,! (1 P0A$C$% M05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D M1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F M]C='5V=WAY>GM\?7Y_<1 (" 0($! ,$!08'!P8%-0$ A$#(3$2!$%187$B M$P4R@9$4H;%"(\%2T? S)&+A7U5F9VAI:FML;6YO8G-T=7 M9W>'EZ>WQ__: P# 0 "$0,1 #\ ]522224I))#NOIQZG77V-JJ9JY[R&M'; M5SDE$UJ4B2K8?4<#/:YV'>R\,^GL,D3QN;])NY3RLS%PZO6RK64US&YY !/[ MHGZ3D:-U6O9;QQX>+B'#^]?I^U,D@XN9BYE7K8MK+JYC0/0+O_ 997_.KKG[2]7>=OJ^G]BVB(W[/0^CZGJ_F^I]/U/\ M,75?6%_4:<&W(Q/1MJK83D8]]>\.8/YQS2'U_1;_ (-_TU.(2QS@31MHSSX^ M:P9HQXAP[Z:_O?\ F6GZ?\GUO2V_RU<^O0O'4L9S MY]#T8J)^COW.];;_ "]GHJMB_6S.Q)&/B8=3'&7,JJ-8/^98KV9]8\K.Z?9E M4T46T4O8W+P\FOU=A?I3=79OK9=38_V?S?JUO4I$_<$^$57#NTH2PGE9X1DD M97[GR_N^'[OI1_407GJ&4YD_9_2 M/;U-P]'^WZ?K+MEP6)]<<_%#:V8N*V@ M&354QU0UYV[7V-;_ -MKL.D=5HZKAC*I!9J665NY:\?29I]+Z6YJBSQEQ<1% M#9N?#\N'VQBA,RD+EJ.'_%;J2Y/ZA_75WUG9FUY+:Z\K%M+JVUR ['<2VFR' MO>YSVO8]EW_6O](GS_KD^GZ\X'U:QVUFBQI&=:X.+VV/JLOQJ:M6L;]"I]G\ MY_2% WWJTERG4OK5GY/UE'U7^KS*CE5-]3/SL@%]5%8#2[TZ*W5.R+_TU/\ MA?3]6STO]-Z .M]<^LWU1KQ\[J5M/6>E66BK*=52I^D]1)3V22Y'ZQ_6[,P>J_5RGIIHNP>NV-#['M<7>FZS&:VRAS7U[ M=]65^>Q;'UKZIE=(^KV;U/###D8K ]@M!IVXI=U.MM5^]P#6<%L_HS].S\W_ %_PMMU)3__1 M]53.W%I#3#HT)$B?AHG224\)U'J^7T_K-WJ86"_,IJD+HOTL_P#]-^5_U+5=,(F$95K0+ACF,L>8R8Q+T&4X<)_PHNL?#$_\_%23V']Z/_2:F#YS_VJMY_._G:?^,Q_3_P!&M'_&KU&H M=$KZ)2/7ZEU.ZH48K/=86L>+O4V-_>LJ;2W^O_QBU;>H]$ZYUW*^K>=@LRFX MM8NJMO8VRM[Q#,ME&]NUMF)ZU#'N8_?OLMK_ $?HH/UNT. =:7,;>W?D>B^['J?N9N_I"2GF/K-A/Z9G_4#!R'#U,-]55SI]LU MOZ>QY#C^9N:NH^OF7BW_ %-ZPVFZNUU=(#PQP<6RYNW?M/MW(.-EU_6(Y]W5 MNAX-K.C6WXA=;;]I=ZM366O%++\&MK<>WG MAW7\C%QLOIM3J?:+'.]*S(KKI_6/LS_\'937_.)*:N%8&_43ZI"?YSJ. W[L M@O\ ^^)OK+T'/^J75?\ G=]7&;L.9ZI@ PT,)W6V,@._5G_3L]OZC=^LU_J_ MKLJWCDT7]0?T'HO2,2^KHCJ[GOO<***S/Z_D9&)AAQG8,C)RGWVV.K]^S&Q/5>^ZMGL>L_ZR M5=5^K'7.B?63(Q<;$Q,39T][,.U]P-+6V>RS[13BNWMP_6]+^=]]-:[#J;\3 MI'4>B=/Z;TC%LNO=DLP7.(QV8Y%9R+_2]'&RG5_:F[_5]*O_ (Q4,SZT8O5/ MJ]T?-OZ11E5]8R10W%SK&BJJP>LT6NM./E-LK_0/].ST/YMZ2GL&/:]H>PAS M' %K@9!!X(*DJO3-O[/QPVNFEC:PUE6,_P!2EK6^UC*+?3HWUM9]']#6K22G M_]+U5))))3RO6?JEF]0ZI?FU7U,9=LAK@Z1M8RO7;_44<#ZGY^*[)+[ZG>OB MW8[8#M'6@-:XS^:V%UB2D]Z=<-Z56S5^XX.,Y*/$29;]9/$_\Q>I?]R:/N>K M6-]4,ZG SL5U]1?EBD,< Z!Z5GK.W?UFKK$D3GR''"NSW!C=S65^_3=^8NH20EFG( M43HNQA9^.,>D=*%PRPQFTV&VG[*TU[&_F.W?SB M!T;ZL]1Z5U7.R_2P'#)K%X_0X];_2=[-/TWZ3_"6KJ4E&V7E6 M_4_)QW=&SL;)W=4Z?_V_P XNN224\\WHO5>F=9SNH]'./D4=5VOR<3*>^GT[JV^FV_'R*:L MK>RYO\_193]/^;O_ ,&GS/JS;U>[(?UFT.;9AMPZ&XS[:@WU!OZA:YGJ>_[3 M>*-E-OK?HL2G_A%T"22GC\CZF9W4\+H>'UFVG)9TVN^G-V[YL;94[$QK:7/! M_6*F^G:][_\ #^]3R?JSUW*Z3T?$S+<3+R.DY(M>ZT/].^JMEE-(L;L?LN3YC;VTN87!P;&4N<')I;G0N4&%G949O3X*"3QD:6-T/@H)"3QK97D^8V]M+F%P<&QE+G!R:6YT+G1I8VME M="YC3PO:V5Y/@H)"3QA3X*"0D)/&1I8W0^"@D)"0D\:V5Y M/F-O;2YA<'!L92YP3YC;VTN M87!P;&4N<')I;G0N4&%G949O3YC;VTN87!P;&4N<')I;G0N=&EC M:V5T+F-L:65N=#PO:V5Y/@H)"0D)/'-T3X*"3PO9&EC=#X*"3QK97D^8V]M+F%P<&QE+G!R M:6YT+E!A9V5&;W)M870N4$U38V%L:6YG/"]K97D^"@D\9&EC=#X*"0D\:V5Y M/F-O;2YA<'!L92YP3YC;VTN87!P;&4N<')I;G0N4&%G949O3X*"0D)"3QD871E/C(P,#@M M,#,M,3A4,3DZ,S0Z-#-:/"]D871E/@H)"0D)/&ME>3YC;VTN87!P;&4N<')I M;G0N=&EC:V5T+G-T871E1FQA9SPO:V5Y/@H)"0D)/&EN=&5G97(^,#PO:6YT M96=E3X*"0D)"3QD871E/C(P,#@M,#,M,3A4 M,3DZ,S0Z-#-:/"]D871E/@H)"0D)/&ME>3YC;VTN87!P;&4N<')I;G0N=&EC M:V5T+G-T871E1FQA9SPO:V5Y/@H)"0D)/&EN=&5G97(^,#PO:6YT96=E3X*"0D) M"3QD:6-T/@H)"0D)"3QK97D^8V]M+F%P<&QE+G!R:6YT+E!A9V5&;W)M870N M4$U!9&IU3X*"0D)"0D\:V5Y/F-O;2YA<'!L92YP3X*"0D)"0D\9&%T93XR,# X+3 S+3$X5#$Y.C,T.C0S M6CPO9&%T93X*"0D)"0D\:V5Y/F-O;2YA<'!L92YP3X*"0D\+V1I8W0^"@D)/&ME>3YC;VTN87!P;&4N M<')I;G0N4&%G949O3X*"0D)"3QD:6-T/@H)"0D)"3QK97D^8V]M M+F%P<&QE+G!R:6YT+E!A9V5&;W)M870N4$U!9&IU3X*"0D)"0D)/')E86P^+3$X/"]R96%L/@H)"0D) M"0D\3YC M;VTN87!P;&4N<')I;G0N=&EC:V5T+F-L:65N=#PO:V5Y/@H)"0D)"3QS=')I M;F<^8V]M+F%P<&QE+G!R:6YT:6YG;6%N86=E3YC M;VTN87!P;&4N<')I;G0N=&EC:V5T+G-T871E1FQA9SPO:V5Y/@H)"0D)"3QI M;G1E9V5R/C \+VEN=&5G97(^"@D)"0D\+V1I8W0^"@D)"3PO87)R87D^"@D) M/"]D:6-T/@H)"3QK97D^8V]M+F%P<&QE+G!R:6YT+E!A<&5R26YF;RY035!A M<&5R3F%M93PO:V5Y/@H)"3QD:6-T/@H)"0D\:V5Y/F-O;2YA<'!L92YP3YC;VTN87!P;&4N<')I;G0N=&EC:V5T+G-T871E M1FQA9SPO:V5Y/@H)"0D)"3QI;G1E9V5R/C$\+VEN=&5G97(^"@D)"0D\+V1I M8W0^"@D)"3PO87)R87D^"@D)/"]D:6-T/@H)"3QK97D^8V]M+F%P<&QE+G!R M:6YT+E!A<&5R26YF;RY0355N861J=7-T961086=E4F5C=#PO:V5Y/@H)"3QD M:6-T/@H)"0D\:V5Y/F-O;2YA<'!L92YP3X*"0D)"0D\:V5Y M/F-O;2YA<'!L92YP3YC;VTN87!P;&4N<')I;G0N=&EC:V5T+FUO9$1A=&4\+VME>3X*"0D) M"0D\9&%T93XR,# X+3 S+3$X5#$Y.C,T.C0S6CPO9&%T93X*"0D)"0D\:V5Y M/F-O;2YA<'!L92YP3X* M"0D\+V1I8W0^"@D)/&ME>3YC;VTN87!P;&4N<')I;G0N4&%P97));F9O+E!- M56YA9&IU3X*"0D)"0D)/')E86P^+3$X/"]R96%L/@H)"0D)"0D\3YC;VTN87!P;&4N<')I M;G0N=&EC:V5T+F-L:65N=#PO:V5Y/@H)"0D)"3QS=')I;F<^8V]M+F%P<&QE M+G!R:6YT:6YG;6%N86=E3YC;VTN87!P;&4N<')I M;G0N=&EC:V5T+G-T871E1FQA9SPO:V5Y/@H)"0D)"3QI;G1E9V5R/C \+VEN M=&5G97(^"@D)"0D\+V1I8W0^"@D)"3PO87)R87D^"@D)/"]D:6-T/@H)"3QK M97D^8V]M+F%P<&QE+G!R:6YT+E!A<&5R26YF;RYP<&0N4$U087!E3X*"0D\9&EC=#X*"0D)/&ME>3YC;VTN87!P;&4N<')I;G0N=&EC:V5T M+F-R96%T;W(\+VME>3X*"0D)/'-T3X*"0D)"3QD:6-T/@H) M"0D)"3QK97D^8V]M+F%P<&QE+G!R:6YT+E!A<&5R26YF;RYP<&0N4$U087!E M3X*"0D)"0D\3X*"0D)"0D\9&%T93XR,# S+3 W+3 Q5#$W.C0Y.C,V6CPO9&%T M93X*"0D)"0D\:V5Y/F-O;2YA<'!L92YP3X*"0D\+V1I8W0^"@D)/&ME>3YC;VTN87!P;&4N<')I;G0N M=&EC:V5T+D%0259E3X*"0D\3X*"3QS=')I;F<^,# N,C \ M+W-T7!E96YU;0 I%4VQI8V54>7!E M $EM9R &8F]U;F1S3V)J8P $ !28W0Q ! !4 M;W @;&]N9P 3&5F=&QO;F< $)T;VUL;VYG _0 M !29VAT;&]N9P E@ #=7)L5$585 $ !N=6QL5$585 M $ !-'1415A4 0 M"6AOD%L:6=N !V1E9F%U;'0 M )=F5R=$%L:6=N96YU;0 ]%4VQI8V5697)T06QI9VX '9&5F875L M= MB9T-O;&]R5'EP965N=6T 115-L:6-E0D=#;VQO)E\K.$P]-UX_-&)Y2D MA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$ @(! @0$ M P0%!@<'!@4U 0 "$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)# M4Q5C+RLX3#TW7C\T:4I(6TE<34 MY/2EM<75Y?569G:&EJ:VQM;F]B7I[?'_]H # ,! (1 Q$ /P#U M5))))2DDD.Z^G'J==?8VJIFKGO(:T=M7.2436I2)*MA]1P,]KG8=[+PSZ>PR M1/&YOTF[E/*S,7#J];*M937,;GD $_NB?I.1HW5:]EO''AXN(MBVLNKF-S"'"?W3'YR,@D$$6#8/9222225))))*4DDDDI22222E)) M))*4DDDDI__0]522224IKX!Y ] N_\ !EE?\ZNN?M+U M=YV^KZ?V+:(C?L]#Z/J>K^;ZGT_4_P Q=5]87]1IP;>OT&F8 M:U_KQQZ9:?I_R?6]+;_+5SZ]"\=2QG/GT/1BHGZ._<[UMO\ +V>BJV+];,[$ MD8^)AU,<95GA&21E?N?+^[X?N^E']1!>>H93F3]G]("T M]O4W#T?[?I^LNV7!8GUQS\4-K9BXK: 9-53'5#7G;M?8UO\ VVNPZ1U6CJN& M,JD%FI996[EKQ])FGTOI;FJ+/&7%Q$4-FY\/RX?;&*$S*0N6HX?\5NI+D_J' M]=7?6=F;7DMKKRL6TNK;7(#L=Q+:;(>][G/:]CV7?]:_TB?/^N3Z?KS@?5K' M;6:+&D9UK@XO;8^JR_&IJU:QOT*GV?SG](4#?>K27*=2^M6?D_64?5?ZO,J. M54WU,_.R 7U45@-+O3HK=4[(O_34_P"%]/U;/2_TWH ZWUSZS?5&O'SNI6T] M9Z59:*LIU5)Q\BK=]!]0%UV/:SVN_G/2_2>G5ZGZ3U$E/9)+D?K'];LS!ZK] M7*>FFB[!Z[8T/L>UQ=Z;K,9K;*'-?7MWU97Y[%L?6OJF5TCZO9O4\,,.1BL# MV"T%S#[FAP[KO M6NJ=/LK:QE;?7Z7[7,-F.'&OU+7/_P!*U^-?7M9]"])3V*2I=)MZG;BEW4ZV MU7[W -9P6S^C/T[/S?\ 7_"VW4E/_]'U5,[<6D-,.C0D2)^&B=))3PG4>KY? M3^LW>IA8+\REP_6!4X$R!8RS^=.VSTW_ /F:T*?K/^U>E]1Q;Z13D-P[K YA MEC@&EKHW>YCF[V^WWK%^M7_BAS/C7_YZJ0NB_2S_ /TWY7_4M5TPB81E6M N M&.8RQYC)C$O093APG_"BYRTL#_D7K'PQ/_/Q6:M+ _Y%ZQ\,3_S\5)/8?WH_ M])J8/G/]S+_Z2FYRZ;H.8[!^J?6<+H+6]"_QH]5HZ@X5?M=K[,&U\@6& MRQE[:JWG\[^=I_XS']/_ $:T?\:O4:AT2OHE(]?J74[JA1BL]UA:QXN]38W] MZRIM+?Z__&+5MZCT3KG7YC M]^^RVO\ 1^B@_5S&Z11E]7JZ1T?&P\KIEIQZ[0X!UII^YF[^ MD)*>8^LV$_IF?]0,'(+?\ 4WK#:;J[ M75T@/#'!Q;+F[=^T^W<@XV77]8CGW=6Z'@VLZ-;?B%UMOVEWJU-9:\4LOP:V MMQ[=S/TOJ>I_P"I8_6_JJ.C=.?B])Z>'=?R,7&R^FU.I]HL<[TK,BNNG]8^S M/_P=E-?\XDIJX5@;]1/JD)_G.HX#?NR"_P#[XF^LO0<_ZI=5_P"=WU<9NPYG MJF ##0PG=;8R []6?].SV_J-WZS7^K^NRK>.31?U!_0>B](Q+ZNB.KN>^]PH MHIR'S?0S#93CY7ZS[['OM975]F_K^Q6.O?6>OHG3L*_J.+-F6ZMF7CM=O%%; MMKUA];'PW6,K<_T_P!+9;3_ #?K)*>;PNH7V?XNL3#Z=[,_K^1D8F&' M&=@R,G*??;8ZOW[,;$]5[[JV>QZS_K)5U7ZL=W#];TOYWWTUKL.IOQ.D=1Z)T_IO2,6RZ]V2S!P8]KVA["',< 6N!D$'@@J2J],V_L_'#:Z:6-K#6 M58S_ %*6M;[6,HM].C?6UGT?T-:M)*?_TO54DDDE/*]9^J6;U#JE^;5?4QEV MR&N#I&UC*]=O]11P/J?GXKLDOOJ=Z^+=CM@.T=: UKC/YK876)*3WIUPWI5; M-7[C@XSDH\1)EOUD\3_S%ZE_W)H^YZM8WU0SJ<#.Q77U%^6*0QP#H'I6>L[= M_6:NL21.?(=R/L[(C\/Y>)L1.QC\QVF.&3Q/_,7J7_=O.O\ JPX=5Z%G MXXQZ1TH7#+#&;38;:?LK37L;^8[=_.('1OJSU'I75<[+]+!R&YF;E9K,EX<, MFL7C]#CUO])WLT_3?I/\):NI24;9>5;]3\G'=T;.QLG=U3I]SKN@224X72.@Y6!C]:JLLK>[JF9D9=);NAK;V,KK9;/YS/3]^Q9S/J5 MQCPWU-[_;_ #BZY))3SS>B]5Z9UG.Z MCTI[_M-XHV4V^M^BQ*?^$70))*>/R/J9G=3P MNAX?6;:FT6X^!13=53 M196P-=5B@BEI_=H#FL_1_P!A6DDDE/\ _]/U5)?*J22GZJ27RJDDI^JDE\JI M)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?J MI)?*J22G_]D .$))300A !5 0$ / $$ 9 !O &( 90 @ % M: !O '0 ;P!S &@ ;P!P $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ &UL;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z>&UP=&L](C,N,2XQ+3$Q,B(^ M"B @(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO&UL;G,Z>&%P M/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(CX*(" @(" @(" @/'AA M<#I#&%P.D-R96%T;W)4;V]L/@H@(" @(" @(" \>&%P.D-R96%T941A=&4^,C P M."TP,RTQ.%0Q,CHS-3HT,"TP-SHP,#PO>&%P.D-R96%T941A=&4^"B @(" @ M(" @(#QX87 Z36]D:69Y1&%T93XR,# X+3 S+3$X5#$R.C,U.C0P+3 W.C P M/"]X87 Z36]D:69Y1&%T93X*(" @(" @(" @/'AA<#I-971A9&%T841A=&4^ M,C P."TP,RTQ.%0Q,CHS-3HT,"TP-SHP,#PO>&%P.DUE=&%D871A1&%T93X* M(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I M;VX@7!E+U)E M7!E/2)2 M97-O=7)C92(^"B @(" @(" @(" @(#QS=%)E9CII;G-T86YC94E$/G5U:60Z M.3(X-S,W,#E&-C&%P34TZ1&5R:79E9$9R;VT^"B @(" @(#PO&UL;G,Z=&EF M9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]T:69F+S$N,"\B/@H@(" @(" @(" \ M=&EF9CI/&UL;G,Z97AI9CTB:'1T<#HO+VYS+F%D;V)E M+F-O;2]E>&EF+S$N,"\B/@H@(" @(" @(" \97AI9CI0:7AE;%A$:6UE;G-I M;VX^-C P/"]E>&EF.E!I>&5L6$1I;65N&EF.D-O;&]R4W!A8V4^,3PO97AI9CI#;VQO&EF.DYA M=&EV941I9V5S=#X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(#PO'!A8VME="!E;F0](G0 9&5S8P 2D!\@'Z @,"# (4 AT")@(O C@"00)+ E0"70)G G$">@*$ HX"F *B M JP"M@+! LL"U0+@ NL"]0, PL#%@,A RT#. -# T\#6@-F W(#?@.* Y8# MH@.N [H#QP/3 ^ #[ /Y! 8$$P0@!"T$.P1(!%4$8P1Q!'X$C 2:!*@$M@3$ M!-,$X03P!/X%#044%]@8&!A8& M)P8W!D@&609J!GL&C :=!J\&P ;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L M![\'T@?E!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60) M>0F/":0)N@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI M"X +F NP"\@+X0OY#!(,*@Q##%P,=0R.#*<,P S9#/,-#0TF#4 -6@UT#8X- MJ0W##=X-^ X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[! ) M$"800Q!A$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2 MPQ+C$P,3(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/ 5$A4T%585>!6; M%;T5X!8#%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$ 891B*&*\8 MU1CZ&2 911EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H< APJ M'%(<>QRC',P<]1T>'4<=:AZ4'KX>Z1\3'SX?:1^4'[\? MZB 5($$@;""8(,0@\"$<(4@A=2&A(B>K)]PH M#2@_*'$HHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K BLV*VDKG2O1+ 4L.2QN M+*(LURT,+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<-]1B)&9T:K1O!' M-4=[1\!(!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I- DU* M39--W$XE3FY.MT\ 3TE/DT_=4"=0<5"[40914%&;4>92,5)\4L=3$U-?4ZI3 M]E1"5(]4VU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+61I9:5FX6@=:5EJF M6O5;15N56^5<-5R&7-9=)UUX7&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A M]6))8IQB\&-#8Y=CZV1 9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E# M:9II\6I(:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q M.G&5&YXS'DJ M>8EYYWI&>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$> J($*@6N! MS8(P@I*"](-7@[J$'82 A..%1X6KA@Z&I+CDTV3 MMI0@E(J4])5?EAMJ(FHI:C!J-VH^:D5J3'I3BEJ:8:IHNF M_:=NI^"H4JC$J3>IJ:H_R#W(O,DZR;G*.,JWRS;+MLPUS+7--:6YQ_GJ>@RZ+SI M1NG0ZEOJY>MPZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q'EZA8:'B(F* ME)66EYB9FJ2EIJ>HJ:JTM;:WN+FZQ,7&Q\C)RM35UM?8V=KDY>;GZ.GJ]/7V M]_CY^A$ @$# @0$ P4$! 0&!@5M 0(#$00A$@4Q!@ B$T%1!S)A%'$(0H$C MD152H6(6,PFQ),'10W+P%^&"-"624QAC1/&BLB8U&50V160G"G.#DT9TPM+B M\E5E=58WA(6CL\/3X_,I&I2DM,34Y/25I;7%U>7U*$=79CAVAI:FML;6YO9G M=X>7I[?'U^?W2%AH>(B8J+C(V.CX.4E9:7F)F:FYR=GI^2HZ2EIJ>HJ:JKK* MVNKZ_]H # ,! (1 Q$ /P#?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>] M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^ MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7 MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z] MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?_0W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z] MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O? MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[ MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7_T=_CW[KW7O?NO=>]^Z]U M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[ MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO= M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[ MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U_]+?X]^Z]U[W M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO= M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[ MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=> M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>] M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?_3 MW^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>] M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^ MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7 MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z] MU[W[KW7_U-_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z] MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O? MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[ MW[KW7O?NO=>]^Z]U_]7?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW3+N'TEO]VW""UL$^*2:18XU_P!,[E5'YGHM;_.GX=1Y-<2WR4Z?-4P) M$J;TQ,F,LLKPG5FXYFPRG6A(!J 2MF'I()$0Y)YM,?B_U=N]/_--J_[S\7\O MEU&3>_7LPMT+,^YVS>*?,7,93C3^U!\/R_CX9X$'HQNV-V[4WMB(-P;,W-M[ M=V!J3:FS>V,UC<_B*@A(Y"(,EBJFKHY3XY5;TN?2P/T(]AZYM;JSE:"\MI(I MQQ5U*L/M# 'J2MJWC:=]LX]QV3=+:\V]OAE@D26,X!P\;,IP0<'@1TH?;'1C MU[W[KW7O?NO=>]^Z]TP;EW5M?9F)GS^\-R8#:F"I2HJ2K!:6\DLYX*BEF/V!03T7[GNVU;)9R;AO.Y MV]I8)\4LTB11C[7D*J/S/1?D^;/Q!>J%&/DQTD)C,8 []C[7CI=8.W.JW/L^/)O-@77_5R]I2O]D]?V4K^5*]1V/?+V;:40CW/V+7JI M_N9 %KP^(OII_2K3SK3HQ6#S^"W/C*7-[;S6)W#AJY/)19?!Y&CRV,K(_P#C MI2U]!-44M0G^*.1[#\T$]M(T-Q"\^/DEW+\D]UU&[>V]Z9/<,S5$TV*P23S4NU-L02^E:';.W4E M;'XFGCB 0NJM43Z=<\LLA9SEEL?+VTP4LWFPV=I8GU_P .W%A*CR8S-X][G]N> M-]!.J,HX5@4[QL>U;]:-9[K9I+$>!/Q*?5&&5/S!SP-1CH9\D>X'-_MUO$6^ M.[(V92S2R08^MJHY309["&I>2JDVSN 4LK4XD>26FEBEIY'D,8FEQ0YUY/ MN>4=R$!8R;=+4PR'B0.*M3&M:BM* @A@!6@['^POO;M?O3RJVX+$EMS/9E4O M;922$9@=$L6HEC!-I8IJ)9&5XV+%0[G=]@SJ=.O>_=>Z)'\YOFAM;X;]8PYZ M6EH]Q]D[L>KQW7.RZB>2&'(UE(D)R&>S34Y6IAVUM]:J)JCQLDM1++%!&R&0 MRQ#/DKD^YYNW(P!C'MT5#+(!P!X*M<:VH:5P "Q!I0P9[\^]NU>RW*R;@\27 M/,UX62SMB2 [*!KEEIW"&'4I>A#.S)&I74734*[M^0?<'R(W7/O#MW>^8W9D M6EG;'4%34/#M_;U/,P)Q^VL! 4Q6#H555!6"-6E(URM)(6AZZ!^3'<_QGW93[MZDWC7X-Q412Y?;E3)+7;0W M13HT?EH-R;=>9*/(0SPIX_,OBK(%):GFAD"N"/?>7-GYCM6M=UM%<4[7&)$/ MJC\13C3*G\0(QU('M[[H<[>U^[Q[OR?O4D#:@9(6):WG I5)H20K@@4U#3(@ MS&Z-1AN#_#7Y;[,^8'4]/OK;\*83=6&EAP_8>RWJ/N*G:^X6A,B&"5ECDK,! MF8HVGQ]5I'DC#QMIFAF1,3>;N5;SE/=&LISKM7&J*2E Z?/T9>##R-",$$]E MO97W@V3WEY1CW_;D$&[0D1WEL35H)J5%#@M%( 6B>G<*J:.CJIMO85ZF#KWO MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z] M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7 MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO_]??X]^Z]U[W[KW7O?NO=>]^ MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UIZ?S7^ MZ,GVM\OMZ[?:K=]L=/Q4G7.W*(27@AJJ*"*OW96M$MHQ75>YJN>%WY=H*6!6 M/[8"Y9^UVSQ[7RG9SZ?\9NR97/G0FB#[ @!'S9CY]<9_O<<[77-OO)OFW&8G M:]F"V<*UP&4![AJ<-33LZD\2L: _" *T_]^Z]U[W[KW1^?Y:'=60Z M6^7_ %9*E;)!M[LC+T_5.ZZ35IIZRBWM54^-PDM1/>.4]S!2MQ;H9T/F#&"6I_IDU+3U(\P.L@_NP<\7')'O)RFXG*[; MN('7;/KWOW7NM,'^9?W5D.Z?E_V MG*];)/M[K?+U'5.U*35JIZ.BV355&-SS\I[8 E+BX03N?,F0 K7_2II6GJ#YD]<3/O/\\7'._O)S8YG+;;MDQL M(%\E6V8I*1Y'Q+CQI-7F&45( Z(-['/6/G7O?NO=>]^Z]U9G_*:[HR/57R]V M?MLUCQ;7[BIJWKS<-&TQ6FDKZBFGR>T*X0,?%)D*?/<^5+NXT5N;0B5#YT! D%?0H23\U6O#K*'[HG.]SRG[Q[-MAG(VK>D: MSF6O:7*E[=J<"XF544\0LL@'Q$'<$]XG==E>O>_=>Z][]U[KWOW7NO>_=>Z] M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7 MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][ M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][] MU[KWOW7NO>_=>Z__T-_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6C!\S\;6XKY<_)JEKT:.>7O;M/)1 MJPD!-%F-YYC+XUQY%1M,F.KHF%AI((TDK8G-7D^1)>5.7&0]HL81^:QJI_F# MUP9][;:>T]X?=&*X4B0[_?../PR7,DB'/JC*1Y>E10]%G]B/J+^O>_=>Z][] MU[H9OCECK)4( )# M&YB (!Q@YSC&<=;Z/O!_KZ .O>_=>ZT*/D)C<6PR1S;'LTL0 C:TA(IZ&-2.OG\ M]QK:XLO<'GJSNV)NHMYO4.R&4^7GQFIL:6%1%WEUED9"K2J?X?B-VXK+98$PJ[E6Q=%,""-)%PQ"DD!O MG&2.+E3F-I/A-E,/S9&5?^-$?Y.I2]D+:XNO>+VOBM2?$&_63GC\$=Q'))P_ MX6K5\O6@J>MYOWA7UWDZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_= M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=> MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K__ MT=_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7 MO?NO=>]^Z]U[W[KW6L!_.@^,^3V=VWC/DCM_'SS;/[2I<=A-XU,$-Z;!]@;? MQL.-H6JFC54IX-T[:Q\+07!+U5#5,[7= 0"[MB6C!.6B8 MU-/4HY-?166G ]U]ULW.%K[F;=;,VS;LJ17+ 8BNX4"+JI@">%%*^L MD4I)JR@TC^YEZP8Z][]U[KWOW7NKA_Y.WQFR?9G?([TS>-E&P.EA43X^KGCM M29KL;)T$M)A<;3E])G.W:&LDR4! M XK$#5B?360$%>(+TX=9F_.A6)!Z^"K&= MB/@<0AL..MK#WC#UUIZ][]U[K5"_G!_&G*=6_(";NO$8]SU_W:8J^:M@B;[; M$=B4%%'!N+$U3*&6*7.T]*F5@9V4U$DU4$6U.Q]Y0^TW,46Y[$-GED_Q^RP M>+1$U1A_I2=!] %K\77)#[Y?MA=X;\\6=L?ZN[[1RP';'>(H$T;>AE"B= M22-9:4 4C)ZJ%]ROUAQU[W[KW7O?NO=7<_R7OC/D]X=MY7Y(;@QLT6S^KJ3( MX/9M540E:?-=@9_'2XZNDHV<&.IAVMMFOF,_'HJJ^E9&U(P$->\',<=IM47+ MT$@-W\;.NI_7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO= M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[ MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=> M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K MW7O?NO=?_]+?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O? MNO=>]^Z]U[W[KW7O?NO=>]^Z]TD-_;!V=VCL[<&P-_[?Q^Z-H;HQ\N,S>$R< M1DIJNFD*NC*Z,D]+64LZ+-3U$+)/3SHDL3I(BL%=C?7>V7<%]8SM%=Q-56'$ M'_ 01@@U!!(((/1-S#R]LO-6R[CR]S#MT=ULUU&4EB<55E/["K*0&1U(9& 9 M2& (UH?DU_)F[CV-ETH7 +1,?7%62OH05'\?7,'W M1^Y3SIL-W=;A[;3+N^Q%B5@=TCO(EXZ3K*0SA1^)&1VX"&N37I)\)_E['DSB M&^,_=QJP6!ECZWW3+C+KJO;-Q8U\,P.G@BHL>+7N/8]'.7*9B\7^L=EI_P": MJ:O]YKJ_EUCHWL=[QK=&S/M?OOC>HLIRG_.4(8_^-]'O^-W\F[OKL/+X[+=[ MO3],[$29)J['"NQF<[#S%*+/]OC,9C9\AB,%]S8QM/D)Q/3DZ_M)AZ2".8?= MS8["*2+9 ;R^I@T*Q*?4D@,U.-%%#PUCJ??;/[EON!S'>6UYS\R[)L 8%DU) M+>2+QHB(7CBU<"TSZDX^"_#K9CZGZGV%TCL+;_6G6FWZ7;>TMMTHIJ&AIAJF MJ)F]=7D\G5O>?)9?)3DRU-3*6DFD8DGZ 8Y[INE]O-]/N.XSF2ZD-23Y>@ X M!0, # '74'E'E'E_D7E_;N6.6-N2VV>V32JKQ)_$[MQ>1SW.[59F-3T(WLOZ M$G7O?NO=!SVQU/L+N[86X.M.R]OTNY-I;DI335U#4C3-3S+ZZ3)XRK2T^-R^ M-G EIJF(K)#(H(/U!,-KW2^V:^@W';IS'=1FH(\_4$<"I&"#@CH-\W M[>Q;C%'%O1-G?4H31FB8^JL 2M?1Q0<-;=W%UR&!OG+Y)*J M&CCO(UJ:+)&Y1)2!0:X"6R M?O"]R+1?:[?_ !2:5-CK"/C)_)K[JW[E\=G?D--%U%L M2)X:FJV]25^.S/8F=@UAA14\&/ER&%VQ%41 AZBKFEJH"0/LV))0![NSV M,4D&P W=\GD% 4_Q^N17M=]ROG?F"\MK_P!QG&S[ "&:%722 M\E%?A 0O% ".+R,SK@>":DKLQ====[+ZFV5M[KOKS;]%M?9NU:!<=@\+0^9H M:6G\DD\LDL]3+/5UM;65,KS5%1/))/43R/)([.S,<<]PW"\W2\N-POYS+=RM M5F/F?L% !0 ==0.6^6]DY0V/;N6^7-N2UV6TCT11)6BBI))+$LS, MQ+.[$N[$LQ+$GI:^T?1YU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^ MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7 MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7_ MT]_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW2:WEO#;77VU-Q;XWCE MJ7!;6VIAZ_/9_+UA?[>@Q>-IWJJN=EC5YIG$<9"1QJ\LKD(BL[ %1:6EQ?W5 MO96D1>ZE<*JCB6)H!_LG &3CHLWK>=LY=VC661N"(@+,<5) M-!A0"S&BJ"2!UJ8_+;^:7WSWWGLKA>M=Q9[ISJ6*JF@Q&%VOD'P^[\]11RLL M&0W=NC%RIDTGK8>9,?15$=!&K^-_N2OF;*7E7VSV/8X(IMQMTN]U(JS.-4:G MS"(<4'DS L>(TUIUR&]W_O7>X'N#N%W9XG0ZZL M.,,;B( Z6\4C6:^,3VKVA@,L,_@NR-^X7.B1YAFL3O#<..RPFDD$TDHR-'D8 M:P223*'9M=RPN>?8]EVS;9XO GVZ!X/X6C0K^PBG6.MGS;S5M]Y^\+#F;<(+ M^I/BQW$R25)J3K5PU2>VNC?DWF(<[3;FJJ?!;+[8J MXJ:BRM#G*EDI\1@][-3104N2H,K.5IH]7V][9R'[I7JW$5TXBMK M]@JR+*V(XKK2 KI(:(L] ZN1XQ=6:2/8F]P#UT@Z ONGNO(],XJ7/?Z$.Z^T M\)2TYJDQ]1$B\LX]G>S[-'N\H M@_?-G;3$T G:1 ?]NL3H/]LP/RZ 7._/%SR3:-N']1=\W:Q1=3MM\=K.R<>, M,EW#<-0"I,<+J!Q(ZKCF_G??%2GFEIZCKCY%P3P2/#/!-M#KB*:&:)BDD4L; M]LJ\.3EKF19%) M!!M[,$$8((-_4$'B.L7_ ^)\3_^?>_(?_T$^MO_ +;7O?\ K+\T?\I]A_O< MW_6CJO\ P=OM'_TSO,?_ &3V7_>PZ]_P^)\3_P#GWOR'_P#03ZV_^VU[]_K+ M\T?\I]A_O_?ZR_-'_*?8?[W-_UHZ]_P=OM'_TSO,?_ &3V7_>PZ%?:7\W[X2[F MJ(Z?);RWAL=I9%B23=NPLZ]/J9BJ&2?:D>Z8H(V:UWD*(@-V*@$@KNO:?G*V M4M':0S4_@E6O['T5_+\NA;L_WR/8S=)%CN=ZO; DT!N+26GYFW$X ^9H!Q) MK0]76?>73G MS VL02"=QV7=]H?1N>VS0'R+H0#_ *5J:6_(GJ>^5^?.2^=8#<YY)LVW'^HV][M8HNIVV^.UF9/MADNX;AL9)BBD4#)(ZK M@F_G??%2GFEIZCKCY%P3P2/#/!-M#KB*:&:)BDD4L;]LJ\(ZQ? M\/B?$_\ Y][\A_\ T$^MO_MM>]_ZR_-'_*?8?[W-_P!:.J_\';[1_P#3.\Q_ M]D]E_P![#KW_ ^)\3_^?>_(?_T$^MO_ +;7OW^LOS1_RGV'^]S?]:.O?\'; M[1_],[S'_P!D]E_WL.O?\/B?$_\ Y][\A_\ T$^MO_MM>_?ZR_-'_*?8?[W- M_P!:.O?\';[1_P#3.\Q_]D]E_P![#H4]I?S@OA-N6=(,INW>NQ3(P19=V["S M4L&HZ=(>79XW:L2LS6U/I1;$L0O/LLNO:;G*V4M%:PS_ .DE6O\ U4T="O9_ MOE>QNZ.L=UO%]85-*W%I*1^9M_J*?:: <20,]'JZS[WZ7[FIC5=5]H[&WZ$C M\M12[;W'C,AE*)+ _P"Y'#QU'\6QC68'340QM8CCGV"=RV3>-H;3N>V3P>A= M"%/V-32?R)ZGOE?G_DGG6(R\I\UV&X "I6&9'=1_3C!\1/L=5/0L>ROH7=>] M^Z]U[W[KW7O?NO=47?,7_A0G\$?@]\CNR_BYW/@/D%5]E=5KM [AJ=D]?[4S MFUZP[VV%MGL7#KALID.Q,)65#1X+=E*D_GI:<)4ZT4NBB0^Z<6)F (I3JTOX MH_)WJSYF?'CJWY-=+UF3JNN>V=O'.X2'.TU%1;BPU51Y"MPFX-L;EHL;D_=>ZKJ M_F)_S0/C-_+%V=UGO'Y&#?N2C[8W?D=I;2V[UI@\%N+=$JX3$'+[AW/58W/[ MHVG -K[>^XH::KF@GGJ4JLG2*L#J[O'[JRH7K3H//Y>'\XKXG?S-=Y=G;'^. MF*[>QN5ZHVSMO=>X*CLW:>V]L4.0Q^Y,GDML[+W=OGY/[JQTLM)/'T-MRCR&RZ>NBEFC9).QMXY;:>U\QC],(8 M5F"?-4[B1-!;UZ/=.B)S\NJL\[_PL@V_3Y&6+;/\O?,9?$B_@K<[\H:+;N1D M_$(QM6269BO(4,VJ]6\#^ETJ]@?\ "Q3J;(UJ1]I?!GL3 M9V.,K!ZK8'=VVNRJU8!]MHD3'[BZ\ZH@>5M4UT-2H'C3U'6WC]7KQ@/DW5V? MP\_GM_RUOFGE<7M'87>"]:=EYF6"GQO5_?.,3K'=.1K*HLM+CL-EJJOR77VY MZHRE30]'@]^ZKU[W[KW1,OGE\YNH MOY=_0%;\C^[L%V%N'8>/W;M;9U50=98?;VV'D-V[IV=2T'9N'V]@]SOD-I5<-'7UC M8_;.ZMXXU,=5/,K4[&L$S+_G(XSQ[]U1E*FAZ.;[]U7K6EW/_P *JOY;>T,G MN' YS8/RXIMR;7S&6P&8V]_HLZ\_B-/EL+DJC%9"C\DG,UQ5-,Y]50HTC MFS>GWZO3O@MZCJ_[H?O;JCY,]1;%[UZ0WEC-^]7=CX6/.[4W/BFD$-73^>:C MK:*LI:A(JS%9K"Y.EGHLA0U,<550UM/+3S(DL;J/=-D$$@\>A<]^ZUU[W[KW M7O?NO=:]WR _X4M?R]_C9W-V_P!#]B;4^3,V_P#I;?>[.O-SP[HK(*;(TT%8J3QI+ M*B2A@'8 $^Z:Z4WOW7NO>_=>ZJ._F;_SD/CA_*QSO2N [KVCV3V!DNY(-W92 M'#]3P[1R6XMK[=VE/@:.3/9;%;LW1M.EDI2BJ0&'B:WNKHA M>M.EI_+(_FL=!_S3MG]N;MZ3VUOO9$O4&],1MC/;4[)CVY3[K?#[EPS93:N[ M9:/:^>W)C*+'9^IQV4I(HONY76;%3F3V]AZNAQ^6W;EJW=6X-H;"Z^V-C>U.O=T; [0Z*W=V M*^8@ZKA[/FZBW3M#M2NVY0U63W'@MB=N?'CMKO;IC)[QP>+HI:J?;\^XJ;/F MDBEGCHI(:>H>+W6RI K6O1YO?NJ]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7__4 MW^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=4Z?SKNQLGM7XO[7V1BZ MJ6E'9O9>+Q^<$;2JM9MO;.,R6XIZ&0QE5(?<5/BY;,2"(2-)^JRW[.;?'=8J: M>LP@;/\ "<'B-5/WD[UR8Z][]U[KDCO&ZR1LR2(RNCHQ5T=2&5E92"K*1<$< M@^]$ @@C'6U8J0RDA@:@CK>Y^+'8=?VQ\;^D.Q,O4-5YK=76>TLAGZM]>JJW M"F)IZ3<%2?(D;?Y1F::=_H1SP6%F.$O,VWIM?,.\[?$M(8KEPH]$U$J/R4CK MOI[3\QW'-WMIR+S)>2%[Z[VNW>5OXIA&%F;('&16/YX)&2/GLBZD'JM;YR?R MX^L_E1@\ONW:E!BMB=\4U+)/B=WTL H\7NZIA4-%B-_4U)$WW\=4B>*/)*C5 MU(2K$S0I]NTB%.)3X6SP)U#&/WW^[5R MO[L6%YN^T6\-AS^J$QW"C2EPPX1W:J.\-32)@#+'@]Z+X9U$-T[7W#LCV M?NS$UF!W-MC+5^"SV&KXQ'68S+8RIDI*ZCJ%5F0O!/$PU*61ARI*D$Y6VMS; MWMO!=VLH>VD0,K#@5(J"/RZXZ[MM6X[%N>X;-N]F]ONEK,\4L;BC)(C%64^5 M00<@D'B"1GI@]O\ 1?U[W[KW7O?NO=.6'S.7V]DZ+-X#*Y+!YG&3I58[+X>N MJL9D\?51WT5-%7T4L%523I?AXW5A_7VW+#%<1O#/$KPL*%6 ((]"#@C[>E5G M>WFW74%]M]W+!>Q-J22-F1T8<&5U(92/4$'JY?X?_P X'L[K>OQ.R?DE-7=I M=>R2P42[Y95D['VI [1QBLKJE54;ZQM, 7F2J_W*$,SK4RZ$IVB'FSVGVW<8 MY;SET+;7]"?#_P!"<^@'^AD^6GL\M(J6&:OLU]\KFGEFXL]C]S9)-VY<)"_5 M<;RW&!J9O^)2+Q8/^ODD2O18S:+\MO@KT?\ .?KFG[?ZDJ]MXCL_/8*FW#LK MLW")X,%OZEFI8Y:+&[XAI81)6PU<""!:YXOXEC9% 8.D;TK1IRKSMO7)6X-M M.ZK(^VHY22%LM$:Y,=>%..FNAQPH2&&5?O!["_/+4?.7)\MM#S5<6ZS6U M[%B*[4J"J70458,**)2OC0D '4JM$=3/=VT]Q;$W1N#9>[L35X+<^ULO7X+/ M8>N3158_*8RHDI:RFE +(WCFC.EU+(ZV925()REM;JWOK:"\M90]M*@96' J M14'KD/O&T;EL&Z[CLF\6CP;K:3/%+&PHR2(Q5E/V$8(J",@D$'I.^U'1;U[W M[KW7O?NO=.&*RV5P61I,OA,GD,/EJ"43T.3Q594X_(T4X!434E;220U--*%8 MC4C*;'VW+%%/&T4T:O$PH0P!!'S!P>E-I=W=ABB4 MEIDK25;7<,GP_\ 07^0'^AGT*]GJHK49I>S MOWRN;.6+FTV7W+DDW?ELD+]10&]@'#46Q]4HXL)?UCQ$IH$;9PV;O+:W8>UL M%O?9&=QVYMI[FQT&5P6=Q4XJ*'(4-0#HEB>RO')&ZLDL3JDL,J-'(JNK*,<+ MRSN;"YGL[R!H[J-BK*PH01_JJ",$9%0>NH^R[UM/,>TV&^[%?QW6T748DBEC M-5=3YCS!!J&4@,K JP# @*;VFZ-.O>_=>Z^1M_.1[ /9G\TSYW;E,JS"A^1N M_P#8DO6$(71!3JZK%L]0'TG6!JUR7UMKI:F$7[.MB__A)3\[/X M=GNW/Y?&^7GPZ:F7@W6\U[WTGZ][]U[KWOW7NOEE?\ "@?YTK\W/YAG80VKF4RG M3GQVCJ.A^K7H:N6HQ&6;:^5K9.P-ZT@!^RJ'W5OF:K2&L@&FKQ%!C_4ZHK>] M=+(UTJ/4]':_X21[\.W_ .8CVWLBHJ&CHNP?BGO,4U.'514;AVIV3U7F*!F2 M2JA618,#+E?T1S2@L" L?E8>'59OA'V]?1;][Z2] %\G_DUT[\/>C=_?(?OC M=$>U.MNO,5_$,K5I$*O*Y6NJ9HZ+"[9VWC!)%)F-S;DRL\5'0TRL@DGE!=XX ME>1/=; +$ <>OE_?S2OYQOR9_F9[_P O3;ASF5ZX^-F+S$DW7/Q[P&4ECV]1 MT5)4$XK/]A3TOVXW]OMXT65ZJK#4E#*SK00TR,_DUTK1 @^?1Q_Y('\B'<'\ MQF5OD)\@:W7>>Y<+6I#F,!M&MJZ:J3#;'PM1%)3 M9?-B)Y'JE>AH?\ICJJC'^ZK))IP/BZWP.J/Y6G\N7I3;%)M/K_X4?&VFQU)! M#3MD=S=4;2W_ +KR"0($B.:WOO[&[FWCG)%Y8&LKIB&9B+%FOOI.78\6/16O MF!_(0_EI_+?:^:I!\?MH= =B55-6O@^T_CS@\5UCEL3F*FTHR68VCMVFH=@[ MTBGJT5JI,GC9JF6-I!#4TTLAF'NK+(Z^=1U\YO\ F,_R\^[/Y:_R)S'0O<"T MV;H:BC&Y.M.S,-1U5)M?L_8M34S4U%N'$Q53328S)TE1 ]-E,9)+++CJV-D$ MD\#4]3/KI2K!Q4=7=_R/?^% _8?QIWALWXM_-/?.5WW\8MPUV-VSL_M/=V1F MR>Z/CS/,)*/&??9JK\N0SO4IJ9((:N"KFDDP%*GGHV%/"]))[IN2,&I49Z^B M!!/!500U---%4TU3%'/3U$$B303P3()(IH98RT2I\T MJZ=%,TNHA"WOW3D7QKU\L;WKI7U]-#_A+EB)<;_*.?"/3WDL^FG 'H"^_#I+-\?6Q-[WTUU[W[KW5"G_"E M[$5&2_D^?(JL@I8ZB/ ;MZ&R]7,Y@#4-/-W?L/ K51"9UD:1ZO-Q06B#2:9B M2- ./$K3>0$@?;Z+W0@>'227XSU?S[WTWU\8CY88RLPGRF^2N&R, M:Q9#$=_]R8RNB61)5BK*#L7<=+4QK+&S1R*DT3 ,I*FUP;>Z]+EX#[.K7/Y( MW\Y#>7\L[MT;'[$J@I1 M&,S0PQ%LWCZ=(P/N8*1TWU21 XJ/BZ^G?L3?6SNS]E;3[&Z]W)B-X[$WUM[$ M;LV?NK U<=?A=P[^DG#!Z5GOW7N MO>_=>Z^2M_.V54_FO?.@(JJ#WCEV(4!06?$89W:PMZG=B2?R3?WKI;'\"_9U M]8O:V&;;NV-N;?>=:I\%@<1AGJEC,2U+8S'T]$TZQ%Y#$LQ@U!2S:;VN?>^D M73][]U[KWOW7NOE#_P ]/YB-\T?YD_?&]<5DUR7775>3_P! '5$D,IGHWV9U M;D,GCJ_+8^;64FQ^[=^5F:S5.X5+T^1C!%UN==+(UTH!Y]&3_P"$T?R^_P!E ME_F3;.Z[S^4^RZ]^6&#J.BLU%/-HH8=]UE5%F^HLH(KKYLK4;QH1@*:Y(5-P MRG238CW6I5JM?,=?3E][Z2=:X/\ ,WPU3FM@_P Y_K:?;&^F.O>_=>Z][]U[KWOW7NO>_=>Z][]U[K_U=_CW[KW7O?N MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW54'\XOJ#*]D_$\[KP-&];D>GMXXW?. M0B@@$]2VTZB@R.WMQO$%0S+%CVRM+7U# Z$IJ.1W!"@K*/M)NT6W M(DKG@$C9CPJ-2?WE/UR!Z][]U[IQQ&)R>?RV+P6%H:C)YG-9&BQ.)QM'&9JO M(9/)5,5'04-+$OJEJ*NJF2-%'+,P'MN66."*6>9PL**68G@ !4D_(#/2FSL[ MK<+RUL+&!I;V>18XT459W=@J*H\RS$ #S)ZWQ_C]UO)T_P!'=1]7SM#)6[$Z M\VEMG*34^GP5.9QF%HX,W5PZ>#'6999I1];A_J?K[PAW[(4L2H_):#KOW[>'ERDP4ZO)- MMVNQE/[=*Q(M9^WY)(-6G_>PY_VW7*/[\O*EIM' MN/L/,UI$J-N^W_JT_%-:L(S(?F86@3_:>M>J8/]^Z]U[W[KW7O?NO M=>]^Z]U?W_)+^2&8I]S[P^,.XLC+4[?R.)K^P.NH:EO(,1FL?44L>[<)0NS& M2.ES5!5+D%A $,?:S_=>Z][]U[KWOW7NK[ M?Y)GR.RN/WGN_P",NX,C)4;>W#BJ_?G7\-5,\@Q6Y,2U,-SX;'*[DQT^=PTA MKVB4"..7'RR !YI"T&^\G+T4EG:]Y]KMQN2VW7,3W=H&-?#FCT^/&E> EC/BE1@-"[#+L3LE>\>>NF? M6*>>"E@FJ:F:*FIJ:*2>HJ)Y$A@@@A0R2S32R%8XHHHU+,S$!0+GCW[KW7Q6 M.Y=_3=K=O]K=HU/D^X[)[)WSOZH\J)'+YMX[HRFXI?(D?H237D3<+P#]/>NE MX% !TJ_C'\@=\_%3Y!]/?(SK>H:'>73N_AA]^ZUU3Q_/-^>0^ WP [,WGMO)M0]Q]NK+TCTH:>5HZ[';OWGB\B,MO*!X MCY:9M@[0I*_*4\Q5HOXG#1PO83CW[J\:ZF'IU\I>6EJ:>.EEGIYX8JV!JJBD MEBDCCJZ9*FHHGJ*5W55J(%K*26(NA*B6)UOJ4@:Z6=7F_P#";C?']S/YP'QE MI)9F@H=]8CNC8]?(/*0?ONE]^9O$PM%#!.\JU.XL!11\Z$C+B1F"H??NFY?@ M/7U(O>^DG7SP/^%4_P \\UW'\K<'\)=HYJICZL^,-'BL[OK'TE4_\.W/WEO3 M;]/EVK*U(F^VKEV!L7.4V/I";R4E=D,K&;%B!H]*85HNKS/6M;\=NE-S_)'O MOIKH#9@MNCN7LW976N'J&B>:#'U6\-P4&$.7K52Q7'8:&L:KJ7)"QT\+NQ"J M2/=/$T!/7V/.C.F=A_';ISK'HKK#%+AM@=3;)V]L3:E!Z&G&)V[CH,?%5Y": M..,5F7R3Q-4UM0P\E35S22O=W8G?2$DDDGCT*OOW6NO>_=>ZU\/^%*OPYP7R M8_EO[\[3H\3%-VE\3*F/N79V6CB K?[F+44.*[>V]/4B*:1<+4[,D;,21J!K MK<#27=$#D^/3L34<#R/7S&/>NE77TV_^$T?S3SGRN_EYXS8&_,Q/F>R/BEN8 M=+9#(5TTE1D\MUU_"J;-=496NF>20O\ 88&>? 1$V=X\ '?4[EVWTEE72V.! MZ,K_ #^?^W07S8_\,?8W_OXNN??NJQ_&O7RC_>NEG7U ?^$S'_;H+H3_ ,/C MO?\ ]_%O#WX=))?C/5^OO?3?7O?NO=4A?\*._P#MS)\R/_+>?_@JNC??NG(O M[1>OEC>]=*^OJ<_\)Q/^W,GPW_\ +AO_ (*KO+WOI)+_ &C=7>^_=-]?'X^1 MG478_?'\Q[Y0=3=1;3R>^NQ]X?*SY)TVUMH858I,QGZW&]B;]S=1C\7!-+"M M5D)*#&3&&%3Y)I (T#.RJ==+00%!/"G1%ZJEJ:*IJ**MIYZ2LI)Y:6KI*J*2 MGJ:6IIY&BGIZB"54EAGAE0JZ, RL"" 1[]U;K9<_D%_SN0GR61J_CKNS+/([;AP]*GW3/UIN'*2AL]CH8P:2:5LI3 M#RBK@KO=-21ZLCXNOI"XS)XW-XW'YG#9"AR^'R]#29/%97&5=/7XW)XVOIXZ MJAR&/KJ626EK:&MI94DBEC=HY(V#*2"#[WTEZG>_=>Z^4W_.8VO!!_.E^5NW MV-EWHG*LDJLE'E_"[*02P)4CCWKI9'_9C[ M.OJR>]](^O>_=>ZJ[_G)_,L?!C^7CW]W)BQ\Y@/]$_34D,R0Y'_ $I] MEQ5.!P>4Q/D9(Y:[96*:OW&4).J##2<,;*?=71=3 >77RY]E_$ON/?OQ:[M^ M8&W<#]STYT%O_JWKW?N68R++!DNU#G:?&UM&-!@GH<'E:+%T=?=UDBFW#C]* MLLCE-=*]0!"^9Z ';&Y<]LSP5?3Y3 M$92CD*L$JL?D*6.6,D$!T!M[]UOK[%GP9^3N!^9?Q$^/WR:P#4JIVUUM@<_G MJ"B7QLZ< M^1F/VU2=J;7K,AD]D9>7<&P-Z[5W5N_KCLSKS.SP+35.7Z_[0ZZSNU>P=F5E M=3QI'5?P[)4Z5L2+'4++&-'OW6@2.'2/ZG^''1_4._)>U\91;]WYVT^%J=M4 MO:7=O;79_>.^L%MJM>GDKMN;.S/:F[-U?W"P.2>DB:LI,''CH:^2)9*I9I;N M?=>+$BGET:7W[K77O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U_];?X]^Z]U[W[KW7 MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U#R&/H.1XG26)RLBD$$&A!&00?(@\# MTS<6]O>6\]I=0K):RHR.C ,K(P*LK*<%6!((."#0]:VORZ_DU[\Q6X\OO3XJ M?8;IVADJB:N_T6Y;+TV)W-MAYF:62AV[F[MC+;Q6?,^J*[44\95+(_P W5065CYZ5*G)[>'7,OWB^Y7S!:;E> M;W[2^'=[-*Q;Z&218YX*Y*0R2L(YHAG2))$E443]4U@V>27+93.4F.2,#D'R^H?IOQ['KPO@ M%_*QH_CSG\=W)WAD3Q3Q0QSU[FOO\$FT;+&\6UM\;MAY0/PT%=">9SJ; .D54YV?= MZ^ZA#[<[A;]^Z]UKA?SW_ /C[/C=_X;O9?_NRV;[R$]D?]Q>8?^:D/^"3KFE] M_O\ Y*_MG_SS7O\ Q^VZH%]SIUSVZ][]U[KWOW7NO>_=>Z][]U[JP#^5OE), M3\[NA9D5W6JKM\XN:)9FA62/*=9;TH0TA"N)$II9UFT$69HQR#9@!/94<.(/ MU_/?_P"/L^-W_AN]E_\ NRV;[ WLC_N+S#_S4A_P2=9!_?[_ .2O[9_\\U[_ M ,?MNJ!?_=>Z][]U[KWOW7NO>_=>Z/G_ "Q:J>D^=?Q^EII#%(^; MW92LP"DF"MZ[WA154=F#"TU+4.A/U ;BQY]@?W(57Y)WX,*C0A_,2QD?S'60 M'W6I9(??OV\>-J,9[A?R:SN%8?FI(_/K=$]X?]=MNBG?/3LA^G_A#\O^TH:A MZ:MV%\9N\=T8N6)YHYCFL3UKN2JP<,$M.R30SU.72"-'5DT.X8LH&H>ZLHJR MCY]?/-_D@_RW\)_,:Z6_F<;'GI*,;[VSTCU33=+9ZM$,<6V^X&\=F3M M735*KC:/<4O5LV%R$W@E*8G)U95D;2'UTID?24ZH!SN#S.V,WF=M;BQE=A-P M;>RN0P>=PV3II:/)8C,XFKFH,GC,A23JDU+74%;3O%+&X#)(A4@$>_=.=;SG M_"3/Y]KGMF]D_P O#?\ F%_B>QFR_Z]\I-]?S0_P":/M'XB_'Y MY-W[2Z=WI3_&?J#$T52[XC='TO@ET_P!>P1';&T/@QL_KNJS$6/I, M=)O#>NS.U>T\OOC?.2AII"?XUO#-;X^^J@5"HTP5&8 A?=;B;4&)]>JV_P"5 M#OF/KG^9?\$MU3RK!2Q_*7IG U]0XC,=-C=X[UQ.SLG52^57414V/STCN0-: MJI*V8 ^_=6?*-]G7U\O>^D77QG/F3V;D>Z/EO\G>VDHZ&:.&&(JOBAC5 %L-=+E%% ^75IW_":_KZCWW_- MX^/%;D((ZJDZ\VYW%V":>5E6-JS']5[JP&'G*E2\DF/S>Y*:IC"E2)858DJK M*?=4E/8>OJ*^]]).O>_=>Z][]U[HN7S$VYC-X_$?Y3;1S<;38;=/QR[OVYEH M5$1:7&9OK/<^,KXU$\4\!9Z6J<#6CISRI''OW6U^(?;U\9;WKI=UN*_\(]=] MUM!\AOF1UBLM3_#MU],=?;[G@ O2&MZ_WQ7;?I99#]PNBI6#LR8):)]2EKNF MD!_#IF?@IZV6_P"?S_VZ"^;'_AC[&_\ ?Q=<^]],Q_&O7RC_ 'KI9U]0'_A, MQ_VZ"Z$_\/CO?_W\6\/?ATDE^,]7Z^]]-]>]^Z]U2%_PH[_[?>NE;_V7Y=7A_P#"A3^1-%V[0[L^=_PQV92TW:N*IFXI*=K M''6@_P"_=*.MO?\ X3S?SSAT'7[8^"GS#WDD?1F7KEQO17<6Z\I4:.F\M6F& M"AZUW5D:KRPT_5&5J_\ BW5DSQ1;;JI629_X9*K8WW3,L=>Y1GK?]5E=5=&5 MT=0R.I#*RL+JRL+AE8&X(^OO?2;KY?\ _-A57_X4&=KHZJZ/\I?C@KHP#*RM MMGIL,K*;AE8&Q!^OO72M/[,?9U]0+WOI)U[W[KW7SZ?^%9OS-/97R9ZK^&&U M,RTVU?CKMI-^=D45-.IIJCM[LS'TU7AJ'(0H\BR5.T.M#234SG0R'<54A7@' MWH]*85H"WKULD_ +^5KM'8W\E['_ :[)Q*XG<7R0ZOK*N-X[FV%O##RLKRXG=.S\U6[>W!C)'7TN]!EL=-$2."4]ZZ5@U M (ZWA/\ A(M\Q!F]A_(+X,[IRROD=D9.'O[J6EJ:EI*F7:FY9,?M;M'#4,4L M@6FQFW=SQ8;(1Q1*==1GZN1K6Y\.D\RY#=;H/O?3'7O?NO=>]^Z]U[W[KW7O M?NO=>]^Z]U[W[KW7O?NO=?_7W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW4 M2N>MBHZF3&TU/65Z0R-24M7624%-45 4F.&>MBH\A)2QNW!<02E?KI/NR!"Z MB1B$KD@5('R%17[*CIF=IUAE:VB5[@*=*LQ12?(%@KE0?72U/0]5U,!2UM1+3X7=%+N7;&5V=N%HE:2V%W)0QRX^>H-./*U+(T5; M#&0988SQ[DS8O;J#F2$R[3S3:R,!5D*.LB?Z9#D"N-0JI/ GK%3W#^\]?^UM M\MGSE[1;M;Q.Q$4ZS026TU,_IS+5":=QC8K*H^-%Z+S_ ,/K=3_\^([#_P#0 MDVW_ ->_9_\ ZR>Z?]'NW_WA^HY_X/?E'_I@=R_YS0_YNO?\/K=3_P#/B.P_ M_0DVW_U[]^_UD]T_Z/=O_O#]>_X/?E'_ *8'_?O\ 63W3_H]V_P#O#]>_X/?E'_I@=R_YS0_YNA=V)_.I^)FY MIH:3=N)[2ZWE?QB>OS6V:#<&#A+WUE*C:.9S6SW M--L"UK+;7 \@KE6_9(JK_P ;Z&&P???]H=T=(=XL]VVQS2KR0)-$/L-O)+*: M?\T1Y4KFEDW5'>74'>>$;G Y.*?(8IYP6AAS>&E\.9P53 M*BDK%64\$I7G3;W'FZ;+NVRS"WW7;Y8)#PU##4_A;X6'S4D=9-.O 2QFDD3'B%D16IFG0J^ROH6]:X7\]_P#X^SXW?^&[ MV7_[LMF^\A/9'_<7F'_FI#_@DZYI??[_ .2O[9_\\U[_ ,?MNJ!? M_=>Z][]U[KWOW7NO>_=>Z/9_+-_[+G^/G_AQ;B_]X3=7L$^XW_*E;]_S33_J MXG4^?=?_ .G\^W7_ #TS?]HL_5AW\]__ (^SXW?^&[V7_P"[+9OL ^R/^XO, M/_-2'_!)UD;]_O\ Y*_MG_SS7O\ Q^VZH%]SIUSVZ][]U[KWOW7NO>_=>Z][ M]U[H]G\LW_LN?X^?^'%N+_WA-U>P3[C?\J5OW_--/^KB=3Y]U_\ Z?S[=?\ M/3-_VBS];I?O#WKMUU2'_P *+.RUZV_E#?*;Q3-#E-_+UAUIB "DS;J[6V8 M,]#(?+$ZJVSJ')E2H>[A05TEB/=.1"KCJJ?_ (1Z;06B^//S+W]XF#;E[GZZ MV@9M=,5D78^Q\EFEB$:QBK1HCV$26=VC;6 @5ED+:'5Y^*CJHO\ X5!_ R7X MW?-6'Y0;,PJTG4WR_BK-SY%J&F\5!@>\MOP4--V3CY_$KK%+O:*>EW(LLSB2 MLKZ_):%T4YM[J\+56GF.J'OB+\F-^?#KY*]-?)CK:9EW7U#O;&;GBH#4/2TV MXL*/)C]U[0R4T2M(F(WEM:MK,75E1K%/5N5LP!'NG& 8$'KZ4/\ ,_\ YLW7 M/Q__ )5\7RVZ0W?!4[P^4NP,-@?BO*DT4>9CW-V5@?N9]TS4L4D[T&1ZCV_- M69"KCD5XX,S0P4,^EY@/>^DJ(2^D^7'K7@_X2>_!"7L;NCLG^8)OZA>IV]TK M)E>K>G9:S5(YJJ'Y&;.RM5_DB^,8^HZ8S6 I_[-=-YOXEDF_MQ1 M:/[#2>OQZU!^+K3,ZOWK5=;=E]=]BT/E^]V#OG:6]:/P%EG^ZVKG\?G:?PLL MU,PE\M -)$D9O_:7ZCW3YR".OM:TM535M-3UM%405='5P155)5TLL=1355-4 M1K+!44\\3/%-!-$X9'4E64@@D'WOI!U\7SY+;,KNN?D;W_U[E(YXLGL/NSM7 M9F1BJE5*F*NVOOK/82KCJ$3T).E10L' X# V]ZZ7#(!ZNG_X3 Y['X?^;;U; MCJQV6IW5U5W=@<2 T $F0I]B5VZ)$82S12.HQ6VZEK1+(]U!*A [K[JDOP'K MZ_=>Z*+\_]_P!)U9\%OF/V)6U$5,FT/C#WIFJ9IO$5GRE- MUIN3^#4$:3/'%+4Y++M!3PHS*))956XO[]U9^_=-]?+R_E'Y"CRW\__ *G\P7X;[,D; U M$E9N;Y-],[5Q=.D&VRL,M7FN[]E8JA\3#!U#(9]ST$$+M22M)E5_R=JTTVNE M$4G!6ZTI_?NG^MY#_A.Y_/2DRQV9_+[^96\IY\NST^W?C/W9NS+4P2LITIX: M7"](;XRV0>&=\BCQ>';&0GEFDJC(F++RP2LNI&5UO<$'GW[JZ?V M7Y=?37][Z2=!+WWW/LSXZ=)]K=\]AU?V6R>H=@;I[!W)(LD4=1/CMKXBJRKX MZ@$S(DV5RLE.M+217U354T<:@LP'OW6P*D#KY5/Q2[&ZT^6?\U79G??SD[*V MIU]UKOOY!9WY ]W[EWE53+MAJ3%Y/)]BP; CCBI:B=L1N/*4%'MREIXH@L%# M4 *(XXO3KI800E%&:=?1B_X>X_E0?]YS](?^?3,__67WZO27PW_AZ^?W_/NS M'Q7[ _F%;Y[S^(?;VQNV^N>^MK[8[$W1/L6:H>AVKVE'!/M7>V(K(ZNGIJ@U MFX)-NT^X99M.B6HS,H7]! ]TICJ% 89'16?Y7?R_K/@M\[/CU\BS5ST^T]M[ MTIMO=H4\)9EKNJ-[(^U.P4>F5)%K9\9M[*2Y&DC86^_HH&!5E##W6W74I'7U M[Z.LI,C24N0Q]535U!74T%915M'/%4TE925,2STU52U,#/#44U1"ZNCHQ5U( M()!][Z1=2??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?__0W^/?NO=> M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=(OL+KO9/:^SLYL#L3;6+W;M#<=& MU%EL)EZ=9Z:="0\,\+^F>BR%%.JS4U3"T=133HLL3I(JL%EAN%YM=W#?;?<- M%=QFJLIH1\O0@C!!J"*@@@]$G,?+>Q\V[+?\O;-WDCH]R;&S-6$%5E=F9WS/BY M:OQI$CU^-J:>HH*EU1$DJ:.1T4(RCWF+R?S$G-&Q6NZ:0MQE)%'!9%^*GR(( M8>8# '/7#[WM]LI_:7W#W?E(S-+MP"S6LC4U26TM2A:@ UHP>)R 7C8J I' M15/8GZB7KWOW7NO>_=>Z6.P^P=[]7[GQN].O-U9O9NZL3)Y*#.8"OGQ]=$"R MM)!(\+!:JBJ- 6:"4/!,GID1E)'M)?6%EN5M)9W]JDUJ_%6 (^WY$>1&1Y'H MZY?YBWWE7=;;>^7-VGLMVA-4EBQ7%D6;9YR=%,H3DBH-2I)Z^?=H]_/\ 7BV* M\VS?ECBYWVY5,P0:4N(F.E;E$X(=79,BU57*LNE9%1:\OY[_ /Q]GQN_\-WL MO_W9;-]C[V1_W%YA_P":D/\ @DZQR^_W_P E?VS_ .>:]_X_;=4"^YTZY[=> M]^Z]U[W[KW7O?NO=>]^Z]T>S^6;_ -ES_'S_ ,.+<7_O";J]@GW&_P"5*W[_ M )II_P!7$ZGS[K__ $_GVZ_YZ9O^T6?JP[^>_P#\?9\;O_#=[+_]V6S?8!]D M?]Q>8?\ FI#_ ().LC?O]_\ )7]L_P#GFO?^/VW5 ON=.N>W7O?NO=>]^Z]U M[W[KW7O?NO='L_EF_P#9<_Q\_P##BW%_[PFZO8)]QO\ E2M^_P"::?\ 5Q.I M\^Z__P!/Y]NO^>F;_M%GZW2_>'O7;KK4K_X5Y=J?W?\ A?\ &_I^"H\%7V;\ MBYMX5,:B[UF#ZMZ^W'1UM*Q)*B!%+$#4&T>GH1W$_+H6?^$F. MV&P?\LW?F9DBE5MZ?+?L[/0S349I_)24'7'3>U8TIJEN:^CBJ]NSD./2D[2Q MVU*U]CK4WQC[.K0/YP/P7I?Y@_P/[?Z.Q])%+V;AJ-.T>CZR0JK4O;>Q:.OJ M]OXX2O\ MP4V],;55NWZF5E<04V6DF52\:6]U5&TL#Y=?)+JJ6IHJFHHJVGG MI*RDGEI:NDJHI*>II:FGD:*>GJ()526&>&5"KHP#*P((!'O72SH?*'?'R!^1 M.(^.OQ2HQLT MSYSL/=DCNB5#IG=W9"KEIDE+/347@IP=$* ;Z1LVIB>M>#_A7[M,UGPW^+F^ MO#(PVY\F:G:?W %/XHCO3JS>F8$+EA]T))_[@ZET'QVC;7SX_>CTY!\1'RZ^ M?7[]TIZ^R7\%.Q#VY\)_B'VA)4?HD7*YSK/;-?EZ>HF MEJ:V5ZJDRMOE9$O>FR\FM.$HWW-DQ3X_MK"/5(?%/EZ/?L,^3F0*KQT>:I"P8OK?72J M)JH!YCJN#^6[\F(?AW\[/B[\CZ^5X-O];=KX*;>LT*O)/'UWN=*K979#4T:> MJ6J&PMR9'Q)]'DT@\$^_=6<:E(Z^PA05]#E*&CR>,K*7(XW(TM/7X_(4%1#5 MT-=0U<*5%)64=73O)!54M5!(KQR(S(Z,""00?>^D74KW[KW7O?NO=:Q/_"IG MYGX7HWX)4WQ?PV61>S_EKN/&XF7'4M1IK\3U%U]F\/NS>N=J##+Y:6#-YVCQ M6$C25 E=35M<$)^WE T>G85JU?(=?-_]^Z5=?4B_X3S?!?,?"7^7KM%]_P"% MEPG<7R*S4O>G86-KZ809?;N.SN+Q^-Z[V97AXXJJ"7#;+Q]/6U-),HDHLKE: MV$BZGWOI)*VILS= M@8*B!IOC[O/-U6F*KQ=#1Q**'J'=60F"4=E\&#R,@HKI3ST$:ZZ4Q2:NUN/6 MJNK,C*Z,R.C!D=25964W5E86*LI%P1]/?NGNCT_&WMCL3N_^8G\3NR^U]U9/ M>^_76^S<+4Y:L2..3)9-,!M^ECJ*N;755DJ-/ M/))-))(WNJD *P'IU]@OWOI%UJ.?\*R_FJO6GQLZO^$^TLNL6[/D7G8>P.S: M.GD!GH^GNMLK3U6!H*^/4DD,6].S:>FFI9%UJZ[:JXW ##5H]/0K4EO3JIW^ M4A_PG*VM_,%^(&'^4O8I;J%J8:JNWOCLS1I L:H(*".4,PF]/NG'ETM0#JV.3_A(%\-SCFBA^4?R93+ M?:A%K9*;JR7'"N\8!J&Q:[,AJ6I3-=A#]X'"^GRD^KWZG3?CMZ#JOG^8S_PF M#V/\1?AKW7\E^F/D!V=VKNWIC T.]?RW.L\/ MG\JU?VA\9I5^/F_!550FR-9B]I8ZCGZRW%*LC-624V4Z[JZ"C>IE+&JR6,K3 MJ)5@-]))5TN?0]7K^_=-]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?_]'? MX]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6K[_/,1!\A^I) B MB1NF(49PHULB;XW:R(S6U%4:1B!] 6/]3[R3]E2?W!NHKCZS_K&G7*[[^*C_ M %Q^3VH-1V0"OV75Q3]E3^T]4E>YEZP:Z][]U[KWOW7NO>_=>ZL8_E1[MR&U MOG+U'3TD\T=%NZEWOM+-P0FWWN/K-E9W*4D$H+HK0P;@P]%4,#?_ #%P-0'N M/O="UCN>2]U9U&N(QNI]")%4G\U9A^?62?W2-WN-J]^.3XX9&$%XEU;R@?B1 MK:610<\!-'$Y_P!+@5IT>+^>_P#\?9\;O_#=[+_]V6S?8,]D?]Q>8?\ FI#_ M ().IV^_W_R5_;/_ )YKW_C]MU0+[G3KGMU[W[KW7O?NO=>]^Z]U[W[KW1[/ MY9O_ &7/\?/_ XMQ?\ O";J]@GW&_Y4K?O^::?]7$ZGS[K_ /T_GVZ_YZ9O M^T6?JP[^>_\ \?9\;O\ PW>R_P#W9;-]@'V1_P!Q>8?^:D/^"3K(W[_?_)7] ML_\ GFO?^/VW5 ON=.N>W7O?NO=>]^Z]U[W[KW7O?NO='L_EF_\ 9<_Q\_\ M#BW%_P"\)NKV"?<;_E2M^_YII_U<3J?/NO\ _3^?;K_GIF_[19^MTOWA[UVZ MZT O^%@':HS?RF^)O2T=2LT?7'0^Z>QI8$E9UI*WMW?L^WI4D07BAJ9:/IRG ME, PQ^?6P'_P )E-MG!?RA>B\H:>6$;RW[WKN0222K(E6* M7MO=6S_N($5B8(E.U#$5:Q+Q,UK,"?#IJ7XSU?U[WTWU\R7_ (4G? V7XB_/ MC-]M;1P:8WI?Y=IE.V=JM0TS0XS#]E0ST M6^,76T=)-'(X:GK5Z]V5/55LT5O)3U^3Q=0I!47\.JS-1=/F>OHA^]])NM:G M_A5GMQ,Y_*VH\FZ4K-L[Y,]1[CB:H0M-&]5@>PMHEZ%@C".J,>ZF4DE1X&D% M[D Z/3L/Q_EU\U_W[I5U]5W_ (3Z]D_Z3OY1'P^R,U0T^1VIMK?/6V1C=IG> MC_T>=I;VVKA:ZD#?2244=NAE_FM?RUNNOYG?Q@ MRW3FY*FCVMV;M6IJMX=%]FRTQEEV1O\ CH):5*7*O!!-75.QMVP::/-TD08O M"(JF-&JJ.E9/=:1RAKY=?+.^57Q)[_\ A7V_G^C_ )&]>Y?8&^<'+*],*N-I M\!NK"_<2P46ZME[@B7^';GVOE/"3!5TS, P:*58YXY(DUTK#!A4'K:H_DU*56BQ'7O:>,Q,60S MRX?;L0CH\-EZ&FJ5IJ(14U7%%!3_ 'GOW3,D1)U+UN0;)^:_PY[(P%'NG87R MK^.F[MOUR*]/E,%W1UUD*<,RAFIJGP;B:2BKH"=,U/,L<\,@*2(K@@;Z8TL. M*GJO?YO?S[?Y=OPPVIFI:?N;:OR*[8IX*N' =.]";EPN^F[MD_-/YT['R&T>N-LUF,W;TIT)NW&_ M:;A[(S5),*S#;W[,V]DH?NL'U_C)XXZG'XFJBCJ\[*$FG2/&JJY+W34DHII4 MYZWT_>^DW5)7_"C#(5.-_DU?,F:DJ6I9YZ;HC'ZT95>6FR7R:Z8H,A3#5?4M M3CJB9' YT,W^O[]TY%_:+U\K[WKI7UNX_P EG^>S\ _@Y_+YZJ^.7?.X>T,? MV7M+7<^W.E^H^T]@8GI; ;- MS.9SG9TVTJ>IRM1O;*[EH,7CZ'$;5S>Y88?%3;9EFDEDK/U-H5"%UGW57C*4 MJ>@D_P"%+.5J\?\ R>/DG24Q00YWMQ?&.OEV^]=*^OJ#?\)G?)O4:.+FK^R-UFKEH!MC8 M6\-PFN@1I)Z(87;V1R1JX8T5WDEIA3:U4*22M@#[]U0<1U\JW^17F)<%_-L^ M#];%#'.T_:];ARDC,JK%N+8V[=OS3 KSY*>')M(H^A90#Q[UTKD^!NOK'^]] M(^O>_=>Z8-U[5VUOK:^XME;SP6*W1M'=V#RNVMT;:SM%!DL+G]OYRAGQN8PV M6Q]4DE-78[)X^IDAFBD4I)&Y4BQ]^Z]PSU\Q?^>9_)QW-_+8[B?L;JW'97._ M#KMS/US];YUC5Y*?JO<529LC-T[O'(S-/4EZ"F$CX"OJG:3*XV%E>26KI*MS MKI7&^L4/Q=5;_!?_ ++:^'?_ (M/\?/_ '[6T??NKM\+?9U]DJ>>"E@FJ:F: M*FIJ:*2>HJ)Y$A@@@A0R2S32R%8XHHHU+,S$!0+GCWOI#U\F#^9Q\GMU?S/? MYF'8V]=A&JW'BM]=D[>Z(^.&$#'3+L7$9F'8_7,%##JJ&I9-[Y>KDS=1$&D" M9#,SZ3IT@:Z6(-"#KZFWQJZ.VU\9_CYTK\?-H:7V[TSUCLOKG'50C6*3)C:F M!H<359NK50 V0SM;325E2WU>HG=CR3[WTD)J2>AN]^ZUTF=Z[/V[V'LW=NP- MX8V#,[2WSMG/;/W1AZI0]-EMN[FQ57AZ^-3\ MI.AMQ?%WY']X_';=?G?-],]H;RZ]GK9X#3',T>W,W5T.'W%!"?I0[EP\=/D* M8CAZ>I1AP1[UTN4Z@#U=U_PF5^;<7Q=_F T'3>[,O_#^L/F!BJ'J>O$\BI04 M/:V.JJG)=.Y>8M(K>>OR]97;>A"A@9=P*S *FI?#IN5:K7S'7TPO>^DO7O?N MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7_TM_CW[KW7O?NO=>]^Z]U[W[KW7O? MNO=>]^Z]U[W[KW7O?NO=:R/\]*A2/NOI3)B1C)5]6Y*A:(@:$3';LR-0DBGZ MEI#E&!'T 0?X^\C_ &4ZU'4^U.E/31< M.0?S\0_L'5&WN:>L#^O>_=>Z][]U[KWOW7NCV?RS?^RY_CY_X<6XO_>$W5[! M/N-_RI6_?\TT_P"KB=3Y]U__ *?S[=?\],W_ &BS]6'?SW_^/L^-W_AN]E_^ M[+9OL ^R/^XO,/\ S4A_P2=9&_?[_P"2O[9_\\U[_P ?MNJ!?_=> MZ][]U[KWOW7NO>_=>Z/9_+-_[+G^/G_AQ;B_]X3=7L$^XW_*E;]_S33_ *N) MU/GW7_\ I_/MU_STS?\ :+/U8=_/?_X^SXW?^&[V7_[LMF^P#[(_[B\P_P#- M2'_!)UD;]_O_ )*_MG_SS7O_ !^VZH%]SIUSVZ][]U[KWOW7NO>_=>Z][]U[ MH]G\LW_LN?X^?^'%N+_WA-U>P3[C?\J5OW_--/\ JXG4^?=?_P"G\^W7_/3- M_P!HL_6Z7[P]Z[==:]G\P3_A/7TQ_,7^3^]/DUV[\CNX-JY3.;3VAM#:FSMB MX+94&'VEB]I8&#'Q)4U^>H,W7;@7(9R2MR$@ H2OW?A5K1B1M=.K*5% .K5/ M@3\0=M? OXF]3?$[:&Z\KOC;O4\>]H\?NK.4$&,RV8.]>QMW]C5DU=0TM564 ML,\%?N^6$^-Q&XC#*D8(C7?5&;4Q;HW_ +]U7JN+^9W_ "U>IOYH'06(Z2[, MW!E=B9':N^\'OW978^W<5C\MN':]?1";&[@H*:ER$M-#58[=&V:^II)HGE$2 M5'VU4R2M2QH?=61RAJ.A _EY?!?K;^73\7-F?&/K/*Y#<]!M_)[CW)N7?&9H MJ;&YS?6[MT926NR.XN<+N[<>Q<_4[NP>$H,_F,?_,W+ MX,?19*JHZ2.?)QX]J4S,S>%)F;0XNA]U96TFM.M?RG_X2 ?$!<2T-7\J?DE- MG3!5*F1I\;UA2XE:EVE^RE;"R;5JZQH*=6C$L8KPTQ5BKQZ@$U3ISQV]!U>U M_+)_E^8;^6G\=,E\;]L]K;C[P=OYG=.!Q^ RV"I-T8;:])7;:>+% MU];15\$6IUHSCR7K8/^#?\A7^7;\%LGA=[;5ZSKNY>XL'/3U^.[=[ MXK*#>V>P>4@\$T5=L_;%-C,1L#:-50UT1EHZVEQ1S%,&TFNDL#[WTVTC-YXZ MN>]^Z;Z][]U[HCO\Q3X1[?\ YAWQ6WE\6-T;]S'6V"WKG]B9JOW7@,-19W+4 MD6R=WXC=@HZ.@R-714>O)-B1!Y79A"'UZ'MI/NK*VDUIUKV8?_A'[\4()Y6S M_P LOD-DZ8Q6ABP^W^M\'/'/K4^26HK<-N&.:+Q@C0(D-R#JL+'5.G?';^$= M*'_H$&^$O_>3'RG_ .I_4O\ ]KCWZG6O';T'3'F?^$?WQ)G^V_N]\KOD7B]/ MF^\_C.%ZTSWGU>+[?[;[';^W/M?%9]>KS:]2VT:3J]3K?CM_".K0?Y4'\F#9 MO\J3>?>.XMA]\[J[:P_=F V+AZS";MV7BL!78&IV-6[AK*2OAS.&SU12Y&.L M_O-4HT34$31@)ID-FU[ZH\FNF.C;?S)?@;MW^8_\9,C\9=U]BY[K# Y;>VSM MX5VYMMX:ASN59=H5L]='BX:/)5E'1HM=+*MY7\GCT B-C]/=51M)K3J@Y?\ MA(!\0AB/"_RJ^2#9[Q,!DEQ?6*XCSF0E)/X(=L/6&)8K*4_B%RPU:@#I&J=. M>.WH.K[_ .6Q\"MM_P M[XRT/QFVEV'G.SL%C=\;QWE2;GW%A:# Y;_?W5=- M5OC:FCQE964X]UH&A!ZUR_ MB]_PF$^/WQ.^0?0WR0Z\^4/=V4WMTGV!@=]28SHI6F^ZJWB,PD4$II;5.G#,2"",=;/'O?377O?NO=>]^Z]T#7R M#Z ZH^4G378'0?=VTZ'>G679> JMO[EPE:JB01RE9J'+XBLTM/A]QX#(PPUV M-KX"M10UU/%/$RR1J1[K8)!!''K6NZ@_X2A_&OISLKJOMG"?*CO'*[MZJ[9V M3V;C:?*[8V%_=S*0;'W/CMST& KL;24E/DXY:RIQD<4U9'7 :"Q6 $BVJ=.F M8D$4ZV//E%TUF_D1\>^W>BHZOMS9>4Z_KNP\#B(,WGMN[;W0J8K=[8 M&CJ:_&14^TZBMHJ.L\P;'5-2E6J2-"(WWTT#0@TZH'^*O_"7[XQ?%3Y,= M"_)+ _(#M[?M=TCNW&[\.S-[8#9;8;<>Z\'0U\F R%/78.DQ-;@8,+NEZ+)P MQL*YKT7B:0^3R)JG3AF)!%.MG+WOIKKWOW7NO>_=>ZUR_P"8+_PG&Z"_F ?+ M'>?RJW+WMV%U7EM_8/8V/W-M39&T]L5M/D,SL[!P[6EW%)F,U4S,*K*[;Q>- MI_&*4"&2C:5FF,VF/73JRE5I3HJ9_P"$C/QIP&9P>Y.MOF-\E-F[CV[D*7-X M?-U6(Z[R^0Q>?Q=5!7X/,8NIQ&(VG44-3BZ^G692KF36JE7C(N?4ZWXQ\U'6 MV1MVCS&.V_@L?N',IN//T.'QE'G-PQ8R'"19[,4U%!!D\S'AJ:>JI\0F4K4> M<4L]^Z]U[W[KW7O?NO=?_3W^/? MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UK0?SUO^9L=$_^([W' M_P"]*GO(OV3_ .27O?\ ST)_QSKF#]_?_E;N0?\ I6S?]7AU1/[FWK ?KWOW M7NO>_=>Z][]U[H]G\LW_ ++G^/G_ (<6XO\ WA-U>P3[C?\ *E;]_P TT_ZN M)U/GW7_^G\^W7_/3-_VBS]6'?SW_ /C[/C=_X;O9?_NRV;[ /LC_ +B\P_\ M-2'_ 2=9&_?[_Y*_MG_ ,\U[_Q^VZH%]SIUSVZ][]U[KWOW7NO>_=>Z][]U M[H]G\LW_ ++G^/G_ (<6XO\ WA-U>P3[C?\ *E;]_P TT_ZN)U/GW7_^G\^W M7_/3-_VBS]6'?SW_ /C[/C=_X;O9?_NRV;[ /LC_ +B\P_\ -2'_ 2=9&_? M[_Y*_MG_ ,\U[_Q^VZH%]SIUSVZ][]U[KWOW7NO>_=>Z][]U[H]G\LW_ ++G M^/G_ (<6XO\ WA-U>P3[C?\ *E;]_P TT_ZN)U/GW7_^G\^W7_/3-_VBS];I M?O#WKMUU7'\A/YM_\NOXJ=J[@Z1^07R:VUUIVGM:FPE9G=HY;:/9>0JJ&EW' MA:#<.%J!7X'966Q%7%78C)0RAH*B0(6*/ID5U7W5@C$5 QT:[X[_ "-Z8^5_ M5& [Q^/V]8NQ.J=TUFX*#;N\:7";EP-#F*C:V>R.U\\:&DW7AL#E9J:@S^(J M:7SB#PR20MXW=1?W[K1!4T/'H4MS[DPNS=M[AW?N2M_AVW=JX/+;DSV0^WJZ MS[#"X.@J,GE*W[2@@JJZJ^UH:61_'#%)*^G2BLQ /NM=56;?_GM_RF]U9_!; M6VW\Q=IYK<6Y\UB=NX##X[8'NT< M]U[W#'58C)U.+Q^;IDAKZ;KRIP^9I:C%Y2GFCJ:&HJ:9UD $A(('NKA'(J!C MH.?^'^?Y07_>;&Q__0&[B_\ M<^_=>\-_P"'HX/Q.^?WQ!^@KINR=T]B?$_M>F[6VCLO=9V3N7(+M3?.R:W%[B_@V+SR4TV [$VQM+<;4<^.R M\1AK%I#1SR)-''*\D$RI[K;*5-&'1M_?NJ])S>&[,%L+:6Z=\[IJYZ#;&R]N M9O=FXZZEQN4S-31X+;N,JLQEZNGP^$HLCFLK/3X^CD=*:CIYZJ=@$BC>1E4^ MZ]QZJ]VC_/._E2;\W9M;8NT/F'M#.[MWMN7 [0VMA*/8_;HJLQN3K9??NJ=$N^6/\PWX<_!K);! MQ7RM[HH>G:KM"AW3D-A2YG9_8>:QNXJ?9-1MRFW3'39G:>T=P8>FKL1)N['% MZ6HGAJ7CJE=(V179?=656:M!T4K_ (?Y_E!?]YL;'_\ 0&[B_P#M<^_=;\-_ MX>O?\/\ /\H+_O-C8_\ Z W<7_VN??NO>&_\/1M?B;_,-^'/SGR/86+^*/=% M#W#4]54NTZS?\N(V?V'@\=MZ'?,FY(MJI+E]W[1V]B:ZJRS;1R)6"EGGGB6E M9I4160M[K3*RTJ.I?RR_F _#[X,R]?1?*WNO#].MVHF[9-@G,;>WKFXMQ+L1 MMKKNL0S;2VSN"&B?$G>>,NM4T#3"IO$)!'+H]UY59JT'6?XG_/?XD?..+?<_ MQ4[CQW;]-UG)MJ'>]9B=L;YP=#A)]WKGGV_3&MW?M?;U)D:JLCVS6,\5(\\E M,B(TZQB: R>Z\RLM*CHW_OW5>JL^SOYUW\KOIKL3>_4W9WRUVGM'L3KC=&:V M9O7;&0V5VO-68'RNY^M]B=N=;9A]Q=>=F[2P&^]C;A?$YK!C/[1W3C*;-;=SD.*W M%CL3FZ2ER^)K(JB$5--#(T4BMIL1[]U4BA(/'I=^_=:Z(I\J?YF?P/\ A3/) MC/DI\FNN.OMT1TR59V#!6U^\^RA331"6DJ9NN-B4&YM[4='7J?V*B>ABIY3? M3(0K$>ZL$9N ZK0;_A4'_*57*_P\=D=N/2?N.P:ELSLG ML9J2DB::OJZ?K[?V*VOO"OH<=&A,]3344U-$!J,FD@G?5"C+Q'1\/?NJ](;L M_LK9/377&_.V^RL]3;6Z]ZSVAN+?>]MQU<534083:VU<559O.9)Z6A@J:ZL: MEQU%(ZP4\4M1,P"1H[LJGW7@*F@X]%I^'7\PKX??/W%[[S7Q([BINVL=UID, M%B][R+LWL/8]7@:WR-I;/S%139*##U1BJ8:>2F=H)$$A>-U7W M5F5EIJ'1S_?NJ]0_=>ZJ$B_G^_R@)HHY4^:^RPLJ)(HEV%W-!*%=0P$D,W6T MF7%?\ "AS^3EF++9OJ+'XJH8R2@J(YF+H"ZW168>ZWX3_ ,/5I72W?'2_R-V)0=F] M#=I;&[=V!DY9J:EW7L# M/?NJ$$8(Z6>]=X[=Z\V;NWL#=]>^+VGL;;.>WCNC)Q4&2RLN.V[MG%5>:S=? M'B\-1Y#+Y)Z/&T4L@IZ2GGJ9BNB*-W*J?=:XXZJ8I?\ A0#_ "?JNFIZN+YK M;.2*J@BJ(TJNO>ZZ*I6.:-9$6HHJWK2GK*2=58!XI8TEC:ZLH8$#W5_#?^'K M/_P_S_*"_P"\V-C_ /H#=Q?_ &N??NO>&_\ #U9CTCW;UA\CNK-H=V=,;H7> MG6&_J.LR.T-U)A\_@H& M2.1O=5((-#QZ%7W[K77O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__]3?X]^Z]U[W M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6L/_//JZA^^>G*%I+TM/U%- M5PQ:4&BHK-Y9^&IDUA1(WDCH(A8DJ-' !)ODC[*JHV/=WIW&[I^0C6G^$]_=>Z][]U[KWO MW7NCV?RS?^RY_CY_X<6XO_>$W5[!/N-_RI6_?\TT_P"KB=3Y]U__ *?S[=?\ M],W_ &BS]6'?SW_^/L^-W_AN]E_^[+9OL ^R/^XO,/\ S4A_P2=9&_?[_P"2 MO[9_\\U[_P ?MNJ!?_=>Z][]U[KWOW7NO>_=>Z/9_+-_[+G^/G_A MQ;B_]X3=7L$^XW_*E;]_S33_ *N)U/GW7_\ I_/MU_STS?\ :+/U8=_/?_X^ MSXW?^&[V7_[LMF^P#[(_[B\P_P#-2'_!)UD;]_O_ )*_MG_SS7O_ !^VZH%] MSIUSVZ][]U[KWOW7NO>_=>Z][]U[H]G\LW_LN?X^?^'%N+_WA-U>P3[C?\J5 MOW_--/\ JXG4^?=?_P"G\^W7_/3-_P!HL_6Z7[P]Z[==?,O_ .%1M+34_P#- MCWQ+!3P0RUO2_2U56R111QR5=2FW:FB2HJG15:HG6CI(H@[DL(HD6^E0!KI7 M#\ ZW*?^$[^'GP?\G#X8451+%-)/B.YLPKPZ] @W#\C>X,_31'6J-Y8*;)HD MG%M:FQ(L3OIB7XVZMJ[5@@JNK^R*6JABJ::IV%O""HIYXTF@G@FV]D8Y89HI M T^]](>OE5_P#"AK#?P'^<9\T* M'[G[KSYSJ#,^7P^#3_>/X\]1[A^VT>6;5]G_ !3PZ[CR:->E=6D:Z61? O6U MU_+N_D*?RJN_O@%\3^W>TOC/6;@[1[6Z Z^WIO3>M/W=\@,+69#<^YMO4N2R M65IL)A>TJ#:./;[FH)C@AQR4R* /&>;^Z9:1PS '%>KG/@W_ "R_B3_+HE[2 M/Q5V?N;9=)W$FQAO;&YS?FZM[4-34=>MO+^ 5V.&ZLCE*G%U3Q;XJXZGQ2B. M=(X+J#'=M]-L[-2O1_O?NJ]:A_\ PK0^8LFQ?CWTU\)-G92^Z?D'N9>Q^R<; M0R,]?'U=USD:==IXFNHU0NU+O7LQXJFE="6,FUYD(LW.CT]"M26].J>/^$K/ MS '1WSMW'\;]QY-J79/RVV3)A,7!+(RTL/;W6D.4W9LBID=M4,"Y+:T^X<:% MLK5%;64B:KJJ-X=.3+5:^G7T=_>^DO03=]X>?GFG MU^"&?)[/S%%%+-XU>3Q1R3@MI!-AP"??NMCB.OD=?RU*6FK?YC7P!HJVG@JZ M.K^;'Q6I:NDJHHZBFJJ:H[UV)%/3U$$JO%-!-$Y5T8%64D$$'WKI8_PM]G7V M'O>^D75?'SA_E@_$/^8IE>K]'I^)V8G4>DO_P )KOY:7PE^?VQOEEE?EOTHO;.0ZQW9U)C] MCU/^D7MC8;82CW5A]^5.>@*]9[[V9'E%K9L#2L#6"H:'QGQ% \FKW7I79=.D M];EGP@_EC?$3^79DNUJ[XH;+W'L*E[G@V1%OG#97?.Z-[XVJDZ]J-YS;7JL? M+O'(9K,8Z>DCWYD(I E7XIHVC+H736=],,[-34>M;+_A8WCZ.38WP&RKP*V0 MH]V?(K'TU3J?5%1Y/#]-U-= %#",K438FG8D@L/$+$ F^CT[!^+I4_\ "._# M+!TA\V-P"=F?)]J]389J7Q@+"N"VCNNM2<2ZR7:I.XF4KI&GQ W.KCPZ]/Q7 MK*FB?OC<-8\<*+&C560H<97UU054 &6K MK:F261OJSN2>3[UTMC^!?LZ^G7_+NPS;=_E_?!C;[SK5/@OAU\9<,]4L9B6I M;&=*[)HFG6(O(8EF,&H*6;3>US[WTD;XF^WJE?\ X48?S?=W_ [KC:OQI^.. MX6V]\F^\]O5.X\EO>B^UERG4/47\0K,$=P8:&KIJF*'=^^\MCJZ@Q56%+XZ* M@K*F,QU2TDJ^ZO$FHU/ =:Y_\A[^3XG\T'LO?_R<^5V5W9G/CIU]O*6BW)%/ MG,TFZOD#V[D88-R9G;^2WH*H9VFPN)H\K35VX:^*I7)U3Y"G@@FCDEFJ:?73 MLCZ ./6^%COY:G\O/%;*CZ\H_A#\5?[H1XXXO\ A=5T1UKD)9:9A=I:K+9# M;E5F:S(M)^Z:R:H>K,P$IE\@U>]])];<=1ZK@^,7\A+H;X=M[Q&.VX0J*J<;&K]B9/-PR4M=-+68^I MF$4+S4M0$H?=6,A9-)X]7]>_=-]:M_\ PJI^9)Z5^%&TOBQM7*M!OWY;;O2D MSM+1R+]]3=.=9UF)W'NEG,+-643;CWE48''Q@A$KJ(Y"+4RI*AT>GH5JU?3K M6U_X3.?,$_&C^9!M7K'/9+[/KSY:X.;I3,I-,Z4=/O\ \KY[J+*&"-6-1D:K M==*^ I[V5!N&1CP+^_=.RK5:^8Z^FU[WTDZ][]U[KXN'Q_PE)D?D-TGMS<>) MIJZ@KNY^M\)G<%FZ"*II*RDJ=\8:ARF)RV+KHGAJ*:HA=X:BGF0JZED=2"1[ MKTN/ ]?0!_GN_P H7X)T_P#+^[\^0?3/QTZHZ#[FZ.P&'W[MS H-U;:W#LW9=/B=I9>#,;9GJ/MII*$55-D4AE698VJ4FWTGC=M0!-0 M>M=?_A+I\B^Q>L/YG&S.C,'E\F_7'R6V3V9MO?6V/NYS@FRG7?7&[.UMJ;ND MQVO[7^.XB?9D^.@JM/D2ERU1$#IE/OPZ MX/FY\.>I.QL*NX^O>T?E3\>NNM][>:NR>+7/;-WMVWM#;.Z,*V3PM;C M;#]__(N>6I4K813#<':N=A5$/(\:1M?ZDCCWNG27Q7]>K:/CA\?>NOBMTCU[ M\?.I8,U2=;]7XBHP.SZ/<.;J]Q9:BQ$^5R&6CH:C,UY-96Q44N1>* R$LD"( MESIO[]U0DDDGCT-WOW6NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K__5W^/?NO=> M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UJ_P#\\W_LH3J/_P 0U'_[ MV^ZO>2?LK_R0=U_Y[/\ K&G7*_[^7_3Q>3_^E*/^TJ?JDCW,O6#/7O?NO=>] M^Z]U[W[KW1[/Y9O_ &7/\?/_ XMQ?\ O";J]@GW&_Y4K?O^::?]7$ZGS[K_ M /T_GVZ_YZ9O^T6?JP[^>_\ \?9\;O\ PW>R_P#W9;-]@'V1_P!Q>8?^:D/^ M"3K(W[_?_)7]L_\ GFO?^/VW5 ON=.N>W7O?NO=>]^Z]U[W[KW7O?NO='L_E MF_\ 9<_Q\_\ #BW%_P"\)NKV"?<;_E2M^_YII_U<3J?/NO\ _3^?;K_GIF_[ M19^K#OY[_P#Q]GQN_P##=[+_ /=ELWV ?9'_ '%YA_YJ0_X).LC?O]_\E?VS M_P">:]_X_;=4"^YTZY[=>]^Z]U[W[KW7O?NO=>]^Z]T>S^6;_P!ES_'S_P . M+<7_ +PFZO8)]QO^5*W[_FFG_5Q.I\^Z_P#]/Y]NO^>F;_M%GZW2_>'O7;KK MYFW_ J2_P"WK^[O_$(=,?\ NFR/O72N'X.C(_R^_P":O_/ Z!^(_1O4?QC_ M );4O=_QZV1B,Q1[![*@^(GRZW]/O+#5N]-Q9G,3P[]Z_P!^T&R,O+39S(UE M(L]%0B*$P:'1Y(WU>ZJR1EB2^?M'1L]]_P ZS_A0[F<-N*@7^47D=O[9R& R M=!E)\K\)/G!6U=!0U6/J*?)UQRXWYAL?!'!32,ZM)3%(M-W+"_OW6A'%_'_, M=:MO\LK_ +>1_P OG_Q=_P"*'_O^=A>_=.O\#?8>OL+^]](NOEC_ /"CO_M\ MW\R/_+>?_@5>C?>NED7]FO5L/PX_X4-?+CX\_%3X^=&;1_EC;O[.VQU/U-LO M8>![#H\_V93TN\\5MS#4V.H]QT\&,Z?S&/BBRD,(E58:JHC ;TR,.??J]4:( M$DZ^MBO^3A_- [D_F6XOY'Y/M[XZTOQVJ.F-U;&P."P25FZ:W(Y.+=5)N^?) M1Y>7<^'P;FNPD^W(XF\--$-4K:T4V'O?33H$I0UZNJ9E16=V5$12SNQ"JJJ+ MLS,;!54"Y)^GOW3?6DM\"<3BOYQO\^CY/_-7=%'3;U^,'Q*Q%3M'JJCR*#*; M9SE.U/GNL>G(8Z6IB,0QFYJ.GW1OH*'U4V4:+TD.2-=*&[(POF>M83Y;]1[[ M_E??S*.QMB[,JZK$[C^+_P @<3OKIW,U+S25$VV,?F,3V;TSG*R0OJGGKMHU MN*EJU#N/,TL99K$GW3JG6H/J.OJZ_&?OK9WRB^/O3?R(V#,LFT^X^N]K[]Q< M'FCGGQ39[&0561V_D'B)C7+[:RIGQ]:@_P U5TTB'E3[WTC(()!Z7/9O_,MN MP?\ PQ]V?^Z&O]^Z\.(Z^1!_+*_[>1_R^?\ Q=_XH?\ O^=A>]=+'^!OL/7V M%_>^D77O?NO=:>G_ L(_P"R;OAW_P")OWW_ .\'#[T>GX.+=(?_ (1S_P#, MMOGA_P"'QT'_ .Z'M3WX=>GXKUNA^]],=:7G_"QC_F6WP/\ _#X[\_\ =#U7 M[T>GX.+=4@_R>_GM_-'^(/6W<6V_@#\+_P#9H=H;PWQ@LWV!GO\ 9=/D1W9_ M=;7HZ^.)1E*FO^$7SER5)63^*(-)CZ*GWOBIL;$9@[!)*BK(5 ME742I9O=-^'%_'_,=:BGS<[2[M[L^6'>G:WR0ZZ_T2=Y[YWQ59OLSK;^Z.[= MA?W/W)+1T4,^(_N=OS(97>&W_'3PQO\ ;Y"IFJ!KN6L1[]T^H 4 ''7UJ/@O M_P!D2_#O_P 58^/G_OI=H^]](F^)OMZ^:W_PH9[/R?9_\W/Y7R5E;+58W8.3 MV%UAMRE?RB+%8S9O6VTZ7(T5,LRJZQ3[LJ,E6-;T--5.RDJ0?>NE<0H@ZWL/ M^$^O6N(ZR_E&_$2EQM+2Q5N\]N;S[*W!6TX4S9;+[Y[&W;F8:JNE%-2&:JH< M#)0T NI,<%%''KD""1M])Y35VZN;]^Z;Z][]U[KWOW7NM*#J=X/YOW_"D3>/ M:-08-S_&/^7=0_:[1;R4]?M_*Y'J+-U6%V;-1U"K)19#^]G?V9R>Z*.=8V6I MPV*2(R$)&YUT^>R*GXCUK3_S2OC1G?Y=O\RSN[KG87WFS\5LSL['=P=!Y;&Q M&D&(V5NJJI.P^N),!.\8CF;8DU4,09E71]]B)1;TD>_=/(=2 ]?4'^"_RBV_ M\TOB+T#\GMN_9PQ=M]=X?.9W&T$WGI=O[YH?+@>P]K12EF>1=K;[Q.1QX9K, MPIM1 )M[WTD8:6(Z-A[]U7KXU77>Z-I['^:.QMZ;^6J;8NT/E!MG=&]%H8*N MJKFVG@.UZ++;C6CI:!XZZIJCAZ2;QQPLLKO8(0Q'O72[BM!Z=;7W\X?^?_TW M\W>@Z[X&_ 7;'9._=R_(OW>N\1O/.[1P[YB3'[:R.2:?S86)\]2466: M7'&/Q3>6.WF5]#.FEVWTRPHQ Z-3[]UKKWOW7NO>_=>Z][]U[KWOW7NO>_=> MZ__6W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UJ_P#\\W_L MH3J/_P 0U'_[V^ZO>2?LK_R0=U_Y[/\ K&G7*_[^7_3Q>3_^E*/^TJ?JDCW, MO6#/7O?NO=>]^Z]U[W[KW1[/Y9O_ &7/\?/_ XMQ?\ O";J]@GW&_Y4K?O^ M::?]7$ZGS[K_ /T_GVZ_YZ9O^T6?JP[^>_\ \?9\;O\ PW>R_P#W9;-]@'V1 M_P!Q>8?^:D/^"3K(W[_?_)7]L_\ GFO?^/VW5 ON=.N>W7O?NO=>]^Z]U[W[ MKW7O?NO='L_EF_\ 9<_Q\_\ #BW%_P"\)NKV"?<;_E2M^_YII_U<3J?/NO\ M_3^?;K_GIF_[19^K#OY[_P#Q]GQN_P##=[+_ /=ELWV ?9'_ '%YA_YJ0_X) M.LC?O]_\E?VS_P">:]_X_;=4"^YTZY[=>]^Z]U[W[KW7O?NO=>]^Z]T>S^6; M_P!ES_'S_P .+<7_ +PFZO8)]QO^5*W[_FFG_5Q.I\^Z_P#]/Y]NO^>F;_M% MGZW2_>'O7;KKYFW_ J2_P"WK^[O_$(=,?\ NFR/O72N'X.MT/\ D#?]N@OA M/_X8^^?_ '\78WO?2>3XVZM.[-_YEMV#_P"&/NS_ -T-?[]U4<1U\AW^6?+% M!_,>_E^S321PPP_-OXIRRRRNL<444?>^PWDDDDNEC_ WV'K M[#7O?2+KY8__ H[_P"WS?S(_P#+>?\ X%7HWWKI9%_9KU]"+^43_P!NOO@3 M_P"*L=._^\?C?>^DK_&WV]6+>_=5ZI6_G\?-7_9+/Y<';F3V_E/X?VGWQ&WQ M[ZN^WJ?!D:/(]@XO)Q[QW/2-"XK:1]J=>465J:>KC73!E31*S*94/OW3D:ZF M'H.J#OY4G\N3^?;\?_C!A=U_$+NWX9=!]??(R#;/>$FW^X\1DLWV;7TVY]H8 M4[:DW#,/CKV'/B(*? ")XL6V0TT<]3.WC22:4MKIQVC)[@21U6=_/;^#7\T7 MKK,[+^8G\PG>?0';,^YY=O\ 0]'V%T!3SXW'PU6,Q^ZMX;;H-U89^KNKR*RH MHADHH*Z2EEEE2B6$OHC@O[J\;(:JM>KV/^$EGS-_T@_'CMWX3[IR:2;CZ!S[ M=F=94\]1>IJNJ^RMKO MLW_F6W8/_AC[L_\ =#7^]]-#B.OD0?RRO^WD?\OG_P 7?^*'_O\ G87O72Q_ M@;[#U]A?WOI%U[W[KW6GI_PL(_[)N^'?_B;]]_\ O!P^]'I^#BW2'_X1S_\ M,MOGA_X?'0?_ +H>U/?AUZ?BO6Z'[WTQUI>?\+&/^9;? _\ \/COS_W0]5^] M'I^#BW2X_P"$>_\ V3=\Q/\ Q-^Q/_>#F]^'7I^*];A?O?3'7R5_YW'_ &]? M^<__ (F_*_\ NFPOO72V/X%Z^H#\%_\ LB7X=_\ BK'Q\_\ ?2[1][Z1M\3? M;U\[#_A2Y\=-P](?S3NU]\5..>#9?R0VYLCN#9.02E6*DJ)4VOB=C[YH&J8( M(*2;*TF]]IUM5,@'F2FKZ:28LTODDUTJB-4'RZVV_P#A,E\F]M=Y?RQ-@]6P M9..??_Q=W-NWJ[>N+EG+5T6&SVZ,]OWKO-+3L3)%AZW;.X?X;3OW>_,Q$F-R]3D:"-*Q%FILLL]BTC!-=/.T9-&!-.BE?SV?@C_-GP. VC\S/ MY@^_?C?W/1[7;;/15+O7H"DJ,9D,/B,W5[OW5M^#=&,?J/J]I<#1YZ:M@CJY MDE:*MR<4276:Z^ZW&R?"H/5F_P#PD:^:)RFV>^?@9NW*:JO:\Y^0/3<-5.[R M-M_+U&,VOVOMVD\I6*GI<1GI,+E*:GBU/++ELA,0 C$^'5)EX-UNJ^]],=?& M]^..Z,2WSJZ&WH8):[!-\L^KMT?:M#'YZS$GN'!Y7P-3U#"+RU%'Z2CG3C MZY(Y 2JU>,W[ANEC_ WV=?7J][Z1=>]^Z]U[W[ MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__]??X]^Z]U[W[KW7O?NO=>]^Z]U[ MW[KW7O?NO=>]^Z]U[W[KW6O'_.%^/'>?TV_[)M.S;E#N>Z002M=: M@'<*2/#05 /E4$=W'/O.?/7*U_RGRCN&XV<6TB-WMX7D57^HF;2Q4$ M!M+ T]"#U4;_ +(Y\P_^\:NY?_0$SO\ ]2^Y5_KIRE_TT5G_ ,Y%_P _6'O^ ML1[S?^$QWK_LEE_Z!Z]_LCGS#_[QJ[E_] 3._P#U+[]_73E+_IHK/_G(O^?K MW^L1[S?^$QWK_LEE_P"@>O?[(Y\P_P#O&KN7_P! 3.__ %+[]_73E+_IHK/_ M )R+_GZ]_K$>\W_A,=Z_[)9?^@>O?[(Y\P_^\:NY?_0$SO\ ]2^_?UTY2_Z: M*S_YR+_GZ]_K$>\W_A,=Z_[)9?\ H'HX_P#+]^)WR8Z_^8?2.\=[]%=G[5VK M@\[G9\QN#.[1RV.Q.-AGV;N2CAEK*VHITA@26KJ8XU+$7=P/J?81Y[YIY[:6Z=%"JKJ6-)$. #G )ZFC[O'M%[H1(T!MIE!9B "S "OF0.CQ_P Y3H;N?N7+FR&0VK)115S44,HIWJDI)2@:VH(UOI[!?M%OFS[1;;XNZ;E#;L[Q%= M;!=5 ]:5XTJ*_;U._P!]3D#G;G7=/;^7E+E6^W&.WM[L2FWB>41EW@*AM(-" MP5J5XT/5*O\ LCGS#_[QJ[E_] 3._P#U+[F+^NG*7_316?\ SD7_ #]80?ZQ M'O-_X3'>O^R67_H'KW^R.?,/_O&KN7_T!,[_ /4OOW]=.4O^FBL_^O^R67_ *!Z]_LCGS#_ .\:NY?_ $!,[_\ 4OOW]=.4O^FBL_\ MG(O^?KW^L1[S?^$QWK_LEE_Z!Z]_LCGS#_[QJ[E_] 3._P#U+[]_73E+_IHK M/_G(O^?KW^L1[S?^$QWK_LEE_P"@>O?[(Y\P_P#O&KN7_P! 3.__ %+[]_73 ME+_IHK/_ )R+_GZ]_K$>\W_A,=Z_[)9?^@>CC_R_?B=\F.O_ )A]([QWOT5V M?M7:N#SN=GS&X,[M'+8[$XV&?9NY*.&6LK:BG2&!):NICC4L1=W ^I]A'GOF MGER_Y2WFTLM[MI;IT4*JNI8TD0X .< GJ:/N\>T7NAR[[SJ2DE*!K:@C6^GL%^T6^;/M%MOB[IN4-N MSO$5UL%U4#UI7C2HK]O4[_?4Y YVYUW3V_EY2Y5OMQCM[>[$IMXGE$9=X"H; M2#0L%:E>-#U2K_LCGS#_ .\:NY?_ $!,[_\ 4ON8OZZO?[(Y\P_P#O&KN7_P! 3.__ %+[]_73E+_IHK/_ M )R+_GZ]_K$>\W_A,=Z_[)9?^@>O?[(Y\P_^\:NY?_0$SO\ ]2^_?UTY2_Z: M*S_YR+_GZ]_K$>\W_A,=Z_[)9?\ H'KW^R.?,/\ [QJ[E_\ 0$SO_P!2^_?U MTY2_Z:*S_P"O^R67_H'KW^R.?,/_O&KN7_T!,[_ /4O MOW]=.4O^FBL_^O^R67_ *!Z./\ R_?B=\F.O_F'TCO' M>_179^U=JX/.YV?,;@SNT>^:>7+_E+>;2RWNVENG10JJZEC21#@ YP">IH^[Q[1>Z'+OO-R+O.^\A;K M:;3!<2F2:6WD2- ;:9068@ LP KYD#K;']XN===>OGY?\*"?Y>WSR^57\SC MLO?O1'Q+[E[*Z\QW5?4^'Q6^MK[5K*O;&=;#[1H:K,ICLS4+28ZLR..RV7EI M'I())9RU.Q"FS!==*8V4( 6SUM'?R&.J>SNC?Y5'Q@ZD[EZ^WCU;V7LJ?N^G MW/LC?> R&VMQXEL]\A^V-W8:2IQF3A@J5@R.WMPTE3$]M+I,+'@^]],R$%R0 M<=6?]LG)+U7V8V&Q%9N#+KU_O,XK XY6?(9O)#;F2-#B*%$CE=ZS)56F&(!6 M)=Q8'Z>_=5'$=?+U^)G\J#^97U[\FOBWVAN[X/?(_$[,VK\B^F]R;@R,O7&7 M:JQ.$VQV1M[,9K)Y'$HIRU!0T>.QTLIFGACA*J"&LPOKI6SI0]PX=?5*][Z1 M]?-X_G/_ ,MK^83\C?YJ'RN[*ZD^)/R![*V+O'=NS(]I;\QFQ,]/M7-8_;W4 MNP]N$X_^ M.?67Q\V%_+&V)5;+Z5ZVP/7>U\_E^G^S=Q[\FPFU<5%C,?D*^/#?(:GQ.7S[ MT].&<4^(2&63]-. =/OW52L1))?J[_\ DR_)?^:%\CIODS6?S)>C,GT:VV)> MG!TMB*GIC-]3XO*09FG[+3L*3&5FX6DGPN&>H1W(H#4H58K4A(M]- MR!!30>JD/YU?Q7^:W\RS^:#\8^CL3\=^Z$^$/3FZNOMA[D[?3:N9H-C3R=EY M7;VY^^>QZ#,RO2I-BL!LRCI<-!5!$B.1P\R13-]S$3KJ\95$)J-76Y3CL=08 MC'T.)Q='38_&8RCI<=CJ"CA2GI*&@HH$IJ2CI:>)5C@IJ:GB5$10%55 L/> M^F.JXOYO?Q*J?FM_+N^2W1N#P[9K?\VR9-^]4T=/3K49.I[-ZTJ8=Z[4P^'O M;PY#=\^'?!ZQ_NC*2 \,??NKHVE@?+K1V_E/?$G^:G\ _G!T+\E:WX-?)ZFZ MW.Z'ZZ[@HJ?K+/U%=5]3[XT8;>536;>I:.JS[Q;9C:'.T@^WCCGK\5 @?U6. MNGW*,I&H5Z^B?\BJ'*9/X^]ZXW!X[)YC-Y#ISLZAP^)PM)49#,Y3*5>R'0_:G6_;NV<;V!UWF\3MO);DZ]W;C=Y;?H6:7$K3XB"F"$D?= M1Z:@*@ETC?33 !B%X=4+_P#"HWXK_*;Y7]??#79OQGZ4[)[IDPF_^VHFABDTR$W\9*^/3D) U5/2:_ MX2T_$WY8?$NA^<^U?DYT-V)TG!N++_';);(DWYMJLPL>ZJR@I.[*3=W\!R M-7- Y# (_O1Z>A(&JIZ??^$N'Q5^4?Q/V+\SMG_)?I7L[I>HSN^>H,KM+']@ M[;R.#H,\:3"=@8[<60VU65$9QF96G:*BCJ9*264*I@U&SQD['7IB#IH>MK/W M[IGKYFO\TW^6/_,=[Y_F(_-GMWKOX7=\;IV%FN\=UU^VMS8/8^3GQ6Z-M05/ M\)PF6U^H]HX+=.(SM!E(H:^GRN.SN M/J(9_(MVD0L"P(8[Z3-\34X5Z!?^9]_++Z6_F?\ 0/\ HD[,JJK:&]MIU60W M%TWVWAJ*FKL[USNVLHXZ:H:2AJ6A7/;.W"M+!%FL49J?[V&")XYJ>J@IJF'W M6T^H]Q]N8#[5L7N#/=);G4?:^QJ6M MBR4^([!V!@*6F[$P%#3F 2&JJL?B*[',9'HJY5+RMKI_5'(*$]74[0_X4G_, M/+X:3;-9_)>^1^X.Y:* TD^(VAD>T1AJO)*])1M628"7X\Y?=6"@_B-5H^Q9 MZZ0'QQ_Y8*;'TF0:)L71T\ MK56G?6G"*M%-3T1?_A0O\??G3_,&^77Q=^+/3/Q\[CKOC'UWFMF0;S[FH-G9 M9^O5[([LS=+B\UNNLS*4TU'6;4ZCZ_HH&J]],=%*_F0?%VG^9OP:^3/QO^T@K,WV)U?F_[C+4$+%!V9M7PN_FS?!KY;]#_+3#? WY M23X?K7L*DH][8.CZTSHS6X^O-PTV^DG7RDND_Y3'\SK9?:O3G8V9^"'R63;VV^VM@Y? M(JG7&5_BD5)@MT8W+UTTN'8+E*6E6DH'_P IFACIKV!D]0OKI872A&H=?0*_ MG6_R[Z'^8Q\(M[]?8#&4LW>G6/W':70&4=(8ZI][8.AF&2V0]886G7%=DX S M8QXO)' N1:AJY=0HU'O?2:-M+5\NM+'^5W\=?YPG\N+Y3;(^2^U_@=\I\IL. M*NAV-W7L"GZZSE/7;_ZLSU512;CQ5-@:@TU=597$^"+)XFK\1IJ?+44/E?Q& M:-M=/N4=::A7KZ)O?9K=U?&?N@[=PFXZC?28<1]O7S!/CE_+%_FZ=-]V]3= M]=?_ #[OK-X=#]J=;]N[9QO8'7>;Q.V\EN3KW=N-WEM^AS%'69?:64R^#J< MIM^..NBH*R"H%.Y430N\;^]=*RZ$$%N/6QEO/^9U_P *@X*2EM_+)V%@3)+* M@J-F?'GMW=-7(?%P*JG?OS>24L49]2.88@S<%F_3[]TUHB_CZV??@'OCY"]E M?#SHG?7RNV_D-J?(CUV$W&-Q9JG7&S;0J29L2M-C8*=4 M)XJ(PLXXE'O?33 !B%X='!]^ZKU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?_]#? MX]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[ MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=> M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>] M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^ MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7 MO?NO=?_1W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^ MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7 MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z] MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O? MNO=>]^Z]U[W[KW7_TM_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z] MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O? MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[ MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO M=>]^Z]U[W[KW7O?NO=>]^Z]U_]/?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[ MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO= M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[ MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=> M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?_4W^/?NO=>]^Z]U[W[KW7O?NO= M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[ MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=> M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>] M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^ MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7_U=_CW[KW7O?NO=>] M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^ MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7 MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z] MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U_];?X]^Z M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z] MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O? MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[ MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO #=?_9 end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Cover Page Document
Apr. 27, 2022
Cover [Abstract]  
Entity Central Index Key 0001179929
Document Type 8-K
Entity Emerging Growth Company false
Title of 12(b) Security Common Stock, $0.001 Par Value
Entity Incorporation, State or Country Code DE
Entity File Number 1-31719
Entity Tax Identification Number 13-4204626
Trading Symbol MOH
Security Exchange Name NYSE
Document Period End Date Apr. 27, 2022
Entity Registrant Name MOLINA HEALTHCARE, INC.
City Area Code 562
Local Phone Number 435-3666
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Amendment Flag false
Entity Address, Address Line One 200 Oceangate, Suite 100,
Entity Address, City or Town Long Beach,
Entity Address, State or Province CA
Entity Address, Postal Zip Code 90802
XML 8 moh-20220427_htm.xml IDEA: XBRL DOCUMENT 0001179929 2022-04-27 2022-04-27 0001179929 false 8-K 2022-04-27 MOLINA HEALTHCARE, INC. DE 1-31719 13-4204626 200 Oceangate, Suite 100, Long Beach, CA 90802 562 435-3666 false false false false Common Stock, $0.001 Par Value MOH NYSE false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 22 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Page Document Sheet http://www.molinahealthcare.com/role/CoverPageDocument Cover Page Document Cover 1 false false All Reports Book All Reports moh-20220427.htm moh-20220427.xsd moh-20220427_lab.xml moh-20220427_pre.xml moh1q22_er.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "moh-20220427.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "moh-20220427.htm" ] }, "labelLink": { "local": [ "moh-20220427_lab.xml" ] }, "presentationLink": { "local": [ "moh-20220427_pre.xml" ] }, "schema": { "local": [ "moh-20220427.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "moh", "nsuri": "http://www.molinahealthcare.com/20220427", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "moh-20220427.htm", "contextRef": "i158e30a8368d49f19818a91b2302b7ba_D20220427-20220427", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page Document", "role": "http://www.molinahealthcare.com/role/CoverPageDocument", "shortName": "Cover Page Document", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "moh-20220427.htm", "contextRef": "i158e30a8368d49f19818a91b2302b7ba_D20220427-20220427", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.molinahealthcare.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.molinahealthcare.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.molinahealthcare.com/role/CoverPageDocument" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.molinahealthcare.com/role/CoverPageDocument" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.molinahealthcare.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.molinahealthcare.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.molinahealthcare.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.molinahealthcare.com/role/CoverPageDocument" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.molinahealthcare.com/role/CoverPageDocument" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.molinahealthcare.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.molinahealthcare.com/role/CoverPageDocument" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.molinahealthcare.com/role/CoverPageDocument" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.molinahealthcare.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.molinahealthcare.com/role/CoverPageDocument" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.molinahealthcare.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.molinahealthcare.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.molinahealthcare.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.molinahealthcare.com/role/CoverPageDocument" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.molinahealthcare.com/role/CoverPageDocument" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.molinahealthcare.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.molinahealthcare.com/role/CoverPageDocument" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.molinahealthcare.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001179929-22-000077-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001179929-22-000077-xbrl.zip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end